WO2023283962A1 - Capside aav modifiée pour thérapie génique et méthodes associées - Google Patents
Capside aav modifiée pour thérapie génique et méthodes associées Download PDFInfo
- Publication number
- WO2023283962A1 WO2023283962A1 PCT/CN2021/106935 CN2021106935W WO2023283962A1 WO 2023283962 A1 WO2023283962 A1 WO 2023283962A1 CN 2021106935 W CN2021106935 W CN 2021106935W WO 2023283962 A1 WO2023283962 A1 WO 2023283962A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- aav9
- cell
- certain embodiments
- raav
- Prior art date
Links
- 210000000234 capsid Anatomy 0.000 title claims abstract description 189
- 238000000034 method Methods 0.000 title claims description 31
- 238000001415 gene therapy Methods 0.000 title description 24
- 239000013603 viral vector Substances 0.000 claims abstract description 18
- 230000010415 tropism Effects 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 161
- 108090000623 proteins and genes Proteins 0.000 claims description 152
- 108091070501 miRNA Proteins 0.000 claims description 118
- 230000014509 gene expression Effects 0.000 claims description 97
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 75
- 108090000565 Capsid Proteins Proteins 0.000 claims description 70
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 70
- 102000040430 polynucleotide Human genes 0.000 claims description 66
- 108091033319 polynucleotide Proteins 0.000 claims description 66
- 239000002157 polynucleotide Substances 0.000 claims description 66
- 239000013598 vector Substances 0.000 claims description 61
- 210000003169 central nervous system Anatomy 0.000 claims description 57
- 230000003612 virological effect Effects 0.000 claims description 53
- 210000001519 tissue Anatomy 0.000 claims description 50
- 239000002245 particle Substances 0.000 claims description 46
- 241000702421 Dependoparvovirus Species 0.000 claims description 42
- 208000035475 disorder Diseases 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 35
- 210000001525 retina Anatomy 0.000 claims description 35
- 208000022873 Ocular disease Diseases 0.000 claims description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 208000002780 macular degeneration Diseases 0.000 claims description 27
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 26
- 239000002679 microRNA Substances 0.000 claims description 26
- 230000035772 mutation Effects 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 23
- 230000002207 retinal effect Effects 0.000 claims description 22
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 22
- 206010013774 Dry eye Diseases 0.000 claims description 21
- 210000004556 brain Anatomy 0.000 claims description 21
- 239000003623 enhancer Substances 0.000 claims description 21
- 108091026890 Coding region Proteins 0.000 claims description 19
- 108091008695 photoreceptors Proteins 0.000 claims description 18
- 238000004806 packaging method and process Methods 0.000 claims description 17
- 238000013518 transcription Methods 0.000 claims description 17
- 230000035897 transcription Effects 0.000 claims description 17
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 16
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 16
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 15
- 206010046851 Uveitis Diseases 0.000 claims description 15
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 15
- 241000701022 Cytomegalovirus Species 0.000 claims description 14
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 14
- 208000015114 central nervous system disease Diseases 0.000 claims description 14
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 13
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 12
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 12
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 12
- 206010023332 keratitis Diseases 0.000 claims description 12
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 208000003435 Optic Neuritis Diseases 0.000 claims description 11
- -1 ProB2 Proteins 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 206010010741 Conjunctivitis Diseases 0.000 claims description 10
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 10
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 claims description 10
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 claims description 10
- 201000011190 diabetic macular edema Diseases 0.000 claims description 10
- 210000004498 neuroglial cell Anatomy 0.000 claims description 10
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 10
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 claims description 9
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 9
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 8
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims description 8
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 claims description 8
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 8
- 239000013608 rAAV vector Substances 0.000 claims description 8
- 208000002691 Choroiditis Diseases 0.000 claims description 7
- 101001078886 Homo sapiens Retinaldehyde-binding protein 1 Proteins 0.000 claims description 7
- 208000003971 Posterior uveitis Diseases 0.000 claims description 7
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 210000002569 neuron Anatomy 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims description 6
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 6
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 6
- 102100022146 Arylsulfatase A Human genes 0.000 claims description 6
- 102100032948 Aspartoacylase Human genes 0.000 claims description 6
- 102100022794 Bestrophin-1 Human genes 0.000 claims description 6
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 claims description 6
- 208000001351 Epiretinal Membrane Diseases 0.000 claims description 6
- 102000003869 Frataxin Human genes 0.000 claims description 6
- 108090000217 Frataxin Proteins 0.000 claims description 6
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 6
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 6
- 102100039214 Guanine nucleotide-binding protein G(t) subunit alpha-2 Human genes 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 6
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 claims description 6
- 101000888142 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-2 Proteins 0.000 claims description 6
- 101000829506 Homo sapiens Rhodopsin kinase GRK1 Proteins 0.000 claims description 6
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims description 6
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 claims description 6
- 206010022941 Iridocyclitis Diseases 0.000 claims description 6
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 6
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 6
- 206010029113 Neovascularisation Diseases 0.000 claims description 6
- 102100037632 Progranulin Human genes 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 102100023742 Rhodopsin kinase GRK1 Human genes 0.000 claims description 6
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims description 6
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims description 6
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 claims description 6
- 201000004612 anterior uveitis Diseases 0.000 claims description 6
- 108010079094 short-wavelength opsin Proteins 0.000 claims description 6
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 5
- 206010039705 Scleritis Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 201000011101 acute retrobulbar neuritis Diseases 0.000 claims description 5
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 5
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 claims description 5
- 208000010217 blepharitis Diseases 0.000 claims description 5
- 201000004709 chorioretinitis Diseases 0.000 claims description 5
- 201000004614 iritis Diseases 0.000 claims description 5
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 208000022670 retrobulbar neuritis Diseases 0.000 claims description 5
- 208000005494 xerophthalmia Diseases 0.000 claims description 5
- 102100035028 Alpha-L-iduronidase Human genes 0.000 claims description 4
- 208000006373 Bell palsy Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 claims description 4
- 101710198317 Centrosomal protein of 290 kDa Proteins 0.000 claims description 4
- 102100029142 Cyclic nucleotide-gated cation channel alpha-3 Human genes 0.000 claims description 4
- 102100029140 Cyclic nucleotide-gated cation channel beta-3 Human genes 0.000 claims description 4
- 101500023984 Drosophila melanogaster Synapsin-1 Proteins 0.000 claims description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 101000771071 Homo sapiens Cyclic nucleotide-gated cation channel alpha-3 Proteins 0.000 claims description 4
- 101000771083 Homo sapiens Cyclic nucleotide-gated cation channel beta-3 Proteins 0.000 claims description 4
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 claims description 4
- 101000611338 Homo sapiens Rhodopsin Proteins 0.000 claims description 4
- 101000609949 Homo sapiens Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Proteins 0.000 claims description 4
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 claims description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
- 108010009047 Myosin VIIa Proteins 0.000 claims description 4
- 101710112083 Para-Rep C1 Proteins 0.000 claims description 4
- 102100022881 Rab proteins geranylgeranyltransferase component A 1 Human genes 0.000 claims description 4
- 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 claims description 4
- 206010038910 Retinitis Diseases 0.000 claims description 4
- 102100040756 Rhodopsin Human genes 0.000 claims description 4
- 102100039174 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Human genes 0.000 claims description 4
- 101000942604 Sphingomonas wittichii (strain DC-6 / KACC 16600) Chloroacetanilide N-alkylformylase, oxygenase component Proteins 0.000 claims description 4
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 4
- 101710119887 Trans-acting factor B Proteins 0.000 claims description 4
- 102100031835 Unconventional myosin-VIIa Human genes 0.000 claims description 4
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 4
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 claims description 4
- 210000000411 amacrine cell Anatomy 0.000 claims description 4
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 4
- 208000036319 cervical spondylosis Diseases 0.000 claims description 4
- 208000002173 dizziness Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 210000002287 horizontal cell Anatomy 0.000 claims description 4
- 230000002132 lysosomal effect Effects 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 208000005801 spondylosis Diseases 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 claims description 3
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 claims description 3
- 102100026440 Arrestin-C Human genes 0.000 claims description 3
- 102100024081 Aryl-hydrocarbon-interacting protein-like 1 Human genes 0.000 claims description 3
- 108700023155 Aspartoacylases Proteins 0.000 claims description 3
- 102100027884 Bardet-Biedl syndrome 4 protein Human genes 0.000 claims description 3
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 3
- 102100034480 Ceroid-lipofuscinosis neuronal protein 6 Human genes 0.000 claims description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 3
- 102100039484 Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' Human genes 0.000 claims description 3
- 102100029362 Cone-rod homeobox protein Human genes 0.000 claims description 3
- 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 claims description 3
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims description 3
- 101000785755 Homo sapiens Arrestin-C Proteins 0.000 claims description 3
- 101000833576 Homo sapiens Aryl-hydrocarbon-interacting protein-like 1 Proteins 0.000 claims description 3
- 101000697660 Homo sapiens Bardet-Biedl syndrome 4 protein Proteins 0.000 claims description 3
- 101000710215 Homo sapiens Ceroid-lipofuscinosis neuronal protein 6 Proteins 0.000 claims description 3
- 101000609790 Homo sapiens Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' Proteins 0.000 claims description 3
- 101000919370 Homo sapiens Cone-rod homeobox protein Proteins 0.000 claims description 3
- 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 claims description 3
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 claims description 3
- 101000997662 Homo sapiens Lysosomal acid glucosylceramidase Proteins 0.000 claims description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 3
- 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 claims description 3
- 101001109052 Homo sapiens NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 claims description 3
- 101000610652 Homo sapiens Peripherin-2 Proteins 0.000 claims description 3
- 101000633511 Homo sapiens Photoreceptor-specific nuclear receptor Proteins 0.000 claims description 3
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 claims description 3
- 101100518359 Homo sapiens RHO gene Proteins 0.000 claims description 3
- 101001092166 Homo sapiens RPE-retinal G protein-coupled receptor Proteins 0.000 claims description 3
- 101000772173 Homo sapiens Tubby-related protein 1 Proteins 0.000 claims description 3
- 101000666127 Homo sapiens Whirlin Proteins 0.000 claims description 3
- 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 claims description 3
- 108010003381 Iduronidase Proteins 0.000 claims description 3
- 102100033356 Lecithin retinol acyltransferase Human genes 0.000 claims description 3
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims description 3
- 102100025136 Macrosialin Human genes 0.000 claims description 3
- 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 claims description 3
- 102100034268 Neural retina-specific leucine zipper protein Human genes 0.000 claims description 3
- 101710181914 Neural retina-specific leucine zipper protein Proteins 0.000 claims description 3
- 102100021584 Neurturin Human genes 0.000 claims description 3
- 108010015406 Neurturin Proteins 0.000 claims description 3
- 102100040375 Peripherin-2 Human genes 0.000 claims description 3
- 102100029533 Photoreceptor-specific nuclear receptor Human genes 0.000 claims description 3
- 108010012809 Progranulins Proteins 0.000 claims description 3
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 claims description 3
- 102100035582 Ral-GDS-related protein Human genes 0.000 claims description 3
- 102100029293 Tubby-related protein 1 Human genes 0.000 claims description 3
- 102100038102 Whirlin Human genes 0.000 claims description 3
- 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 102000002717 c-Mer Tyrosine Kinase Human genes 0.000 claims description 3
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims description 3
- 230000001886 ciliary effect Effects 0.000 claims description 3
- 108010084957 lecithin-retinol acyltransferase Proteins 0.000 claims description 3
- 108010074774 long-wavelength opsin Proteins 0.000 claims description 3
- 210000002161 motor neuron Anatomy 0.000 claims description 3
- LBCGUKCXRVUULK-QGZVFWFLSA-N n-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1h-imidazol-1-yl)-6-methylpyrimidin-4-yl]-d-prolinamide Chemical compound N=1C(C)=CC(N2[C@H](CCC2)C(=O)NCCC=2C=C3OCOC3=CC=2)=NC=1N1C=CN=C1 LBCGUKCXRVUULK-QGZVFWFLSA-N 0.000 claims description 3
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 210000005167 vascular cell Anatomy 0.000 claims description 3
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 2
- 101710191797 Gamma-enolase Proteins 0.000 claims 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 230000001537 neural effect Effects 0.000 abstract description 7
- 230000001976 improved effect Effects 0.000 abstract description 6
- 230000027455 binding Effects 0.000 description 104
- 101710132601 Capsid protein Proteins 0.000 description 72
- 101710197658 Capsid protein VP1 Proteins 0.000 description 72
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 72
- 101710108545 Viral protein 1 Proteins 0.000 description 72
- 239000002773 nucleotide Substances 0.000 description 64
- 125000003729 nucleotide group Chemical group 0.000 description 64
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 51
- 238000002347 injection Methods 0.000 description 41
- 239000007924 injection Substances 0.000 description 41
- 239000013607 AAV vector Substances 0.000 description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 description 28
- 210000001508 eye Anatomy 0.000 description 28
- 230000006870 function Effects 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 25
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 238000006467 substitution reaction Methods 0.000 description 24
- 238000010361 transduction Methods 0.000 description 23
- 230000026683 transduction Effects 0.000 description 23
- 230000000295 complement effect Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 108091092195 Intron Proteins 0.000 description 18
- 108700019146 Transgenes Proteins 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 238000007913 intrathecal administration Methods 0.000 description 15
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 14
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 150000007523 nucleic acids Chemical group 0.000 description 14
- 108010054624 red fluorescent protein Proteins 0.000 description 14
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 13
- 210000001616 monocyte Anatomy 0.000 description 13
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 12
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 12
- 241000649045 Adeno-associated virus 10 Species 0.000 description 12
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 238000012384 transportation and delivery Methods 0.000 description 12
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 11
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 11
- 241000649046 Adeno-associated virus 11 Species 0.000 description 10
- 241000649047 Adeno-associated virus 12 Species 0.000 description 10
- 241000425548 Adeno-associated virus 3A Species 0.000 description 10
- 241000958487 Adeno-associated virus 3B Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 230000007547 defect Effects 0.000 description 10
- 210000004443 dendritic cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 241000300529 Adeno-associated virus 13 Species 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 108020005176 AU Rich Elements Proteins 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 8
- 206010025421 Macule Diseases 0.000 description 8
- 108700011259 MicroRNAs Proteins 0.000 description 8
- 239000004055 small Interfering RNA Substances 0.000 description 8
- 125000006850 spacer group Chemical group 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 108091027967 Small hairpin RNA Proteins 0.000 description 7
- 230000003042 antagnostic effect Effects 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000000278 spinal cord Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 101150044789 Cap gene Proteins 0.000 description 6
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 6
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 6
- 241000125945 Protoparvovirus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000027073 Stargardt disease Diseases 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108091029500 miR-183 stem-loop Proteins 0.000 description 6
- 238000007431 microscopic evaluation Methods 0.000 description 6
- 201000007714 retinoschisis Diseases 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 5
- 108020005004 Guide RNA Proteins 0.000 description 5
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 108091023045 Untranslated Region Proteins 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 201000006754 cone-rod dystrophy Diseases 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000010362 genome editing Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 239000002924 silencing RNA Substances 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 238000010453 CRISPR/Cas method Methods 0.000 description 4
- 208000006992 Color Vision Defects Diseases 0.000 description 4
- 102100034235 ELAV-like protein 1 Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- 101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 description 4
- 102100023057 Neurofilament light polypeptide Human genes 0.000 description 4
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 4
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 4
- 201000000761 achromatopsia Diseases 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 201000007254 color blindness Diseases 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108010000720 Excitatory Amino Acid Transporter 2 Proteins 0.000 description 3
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001018717 Homo sapiens Mitofusin-2 Proteins 0.000 description 3
- 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 description 3
- 101000996052 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 108091033773 MiR-155 Proteins 0.000 description 3
- 108091027559 Mir-96 microRNA Proteins 0.000 description 3
- 102100033703 Mitofusin-2 Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 3
- 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 description 3
- 238000010459 TALEN Methods 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 108091044988 miR-125a stem-loop Proteins 0.000 description 3
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 description 3
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 description 3
- 108091091360 miR-125b stem-loop Proteins 0.000 description 3
- 108091079658 miR-142-1 stem-loop Proteins 0.000 description 3
- 108091071830 miR-142-2 stem-loop Proteins 0.000 description 3
- 108091023796 miR-182 stem-loop Proteins 0.000 description 3
- 108091063344 miR-30b stem-loop Proteins 0.000 description 3
- 108091029119 miR-34a stem-loop Proteins 0.000 description 3
- 108091086713 miR-96 stem-loop Proteins 0.000 description 3
- 108091070961 miR-96-3 stem-loop Proteins 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000790 retinal pigment Substances 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 description 2
- 102100022440 Battenin Human genes 0.000 description 2
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 2
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 2
- 208000022526 Canavan disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000033810 Choroidal dystrophy Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102100036511 Dehydrodolichyl diphosphate synthase complex subunit DHDDS Human genes 0.000 description 2
- 102100031809 Espin Human genes 0.000 description 2
- 208000009119 Giant Axonal Neuropathy Diseases 0.000 description 2
- 102100037410 Gigaxonin Human genes 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 101000928713 Homo sapiens Dehydrodolichyl diphosphate synthase complex subunit DHDDS Proteins 0.000 description 2
- 101000978705 Homo sapiens Nephrocystin-4 Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 102000004627 Iduronidase Human genes 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 2
- 108091046841 MiR-150 Proteins 0.000 description 2
- 108091028066 Mir-126 Proteins 0.000 description 2
- 108091062140 Mir-223 Proteins 0.000 description 2
- 108091060585 Mir-31 Proteins 0.000 description 2
- 208000026072 Motor neurone disease Diseases 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 102100021831 Myelin-associated glycoprotein Human genes 0.000 description 2
- 102100023192 Nephrocystin-4 Human genes 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 102100038931 Proenkephalin-A Human genes 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010056354 Ubiquitin C Proteins 0.000 description 2
- 208000014769 Usher Syndromes Diseases 0.000 description 2
- 102100037930 Usherin Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000576 arachnoid Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 102220408030 c.1336T>C Human genes 0.000 description 2
- 102220346620 c.1720A>T Human genes 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 208000003571 choroideremia Diseases 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 2
- 108091064157 miR-106a stem-loop Proteins 0.000 description 2
- 108091056924 miR-124 stem-loop Proteins 0.000 description 2
- 108091032320 miR-146 stem-loop Proteins 0.000 description 2
- 108091024530 miR-146a stem-loop Proteins 0.000 description 2
- 108091074057 miR-16-1 stem-loop Proteins 0.000 description 2
- 108091091751 miR-17 stem-loop Proteins 0.000 description 2
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 2
- 108091031103 miR-181a stem-loop Proteins 0.000 description 2
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 description 2
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 description 2
- 108091050874 miR-19a stem-loop Proteins 0.000 description 2
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 2
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 2
- 108091031479 miR-204 stem-loop Proteins 0.000 description 2
- 108091032382 miR-204-1 stem-loop Proteins 0.000 description 2
- 108091085803 miR-204-2 stem-loop Proteins 0.000 description 2
- 108091089766 miR-204-3 stem-loop Proteins 0.000 description 2
- 108091073500 miR-204-4 stem-loop Proteins 0.000 description 2
- 108091053626 miR-204-5 stem-loop Proteins 0.000 description 2
- 108091049679 miR-20a stem-loop Proteins 0.000 description 2
- 108091062762 miR-21 stem-loop Proteins 0.000 description 2
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 2
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 2
- 108091088477 miR-29a stem-loop Proteins 0.000 description 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 2
- 108091007432 miR-29b Proteins 0.000 description 2
- 108091047189 miR-29c stem-loop Proteins 0.000 description 2
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 description 2
- 108091030938 miR-424 stem-loop Proteins 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003446 pia mater Anatomy 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 108010074732 preproenkephalin Proteins 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 102220214569 rs1060502907 Human genes 0.000 description 2
- 102220231840 rs1064797305 Human genes 0.000 description 2
- 102200119083 rs118204039 Human genes 0.000 description 2
- 102200062143 rs132630330 Human genes 0.000 description 2
- 102200154191 rs137853843 Human genes 0.000 description 2
- 102220282579 rs1555591854 Human genes 0.000 description 2
- 102200038664 rs199472801 Human genes 0.000 description 2
- 102220201261 rs201339004 Human genes 0.000 description 2
- 102220122077 rs372565083 Human genes 0.000 description 2
- 102220014665 rs397517216 Human genes 0.000 description 2
- 102220035394 rs483352828 Human genes 0.000 description 2
- 102200100757 rs62637007 Human genes 0.000 description 2
- 102220215441 rs756472919 Human genes 0.000 description 2
- 102220101445 rs878853486 Human genes 0.000 description 2
- 102200010124 rs878854402 Human genes 0.000 description 2
- 102220158313 rs886063623 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000004489 tear production Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 102100038568 Age-related maculopathy susceptibility protein 2 Human genes 0.000 description 1
- 241001135972 Aleutian mink disease virus Species 0.000 description 1
- 241000702419 Ambidensovirus Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102220603295 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3_S414N_mutation Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000035678 Autosomal dominant Charcot-Marie-Tooth disease type 2A2 Diseases 0.000 description 1
- 101710199232 Battenin Proteins 0.000 description 1
- 102100026031 Beta-glucuronidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 201000008988 Charcot-Marie-Tooth disease type 2A2 Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102100034622 Complement factor B Human genes 0.000 description 1
- 102100035432 Complement factor H Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 238000010442 DNA editing Methods 0.000 description 1
- 102100031867 DNA excision repair protein ERCC-6 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010053101 ELAV Proteins Proteins 0.000 description 1
- 102000016662 ELAV Proteins Human genes 0.000 description 1
- 102100021650 ER membrane protein complex subunit 1 Human genes 0.000 description 1
- 102100032055 Elongation of very long chain fatty acids protein 1 Human genes 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 108091007413 Extracellular RNA Proteins 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100028065 Fibulin-5 Human genes 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108050003250 Gigaxonin Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108091007417 HOX transcript antisense RNA Proteins 0.000 description 1
- 102100028893 Hemicentin-1 Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000808726 Homo sapiens Age-related maculopathy susceptibility protein 2 Proteins 0.000 description 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
- 101000851684 Homo sapiens Chimeric ERCC6-PGBD3 protein Proteins 0.000 description 1
- 101000710032 Homo sapiens Complement factor B Proteins 0.000 description 1
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 description 1
- 101000920783 Homo sapiens DNA excision repair protein ERCC-6 Proteins 0.000 description 1
- 101000896333 Homo sapiens ER membrane protein complex subunit 1 Proteins 0.000 description 1
- 101000921370 Homo sapiens Elongation of very long chain fatty acids protein 1 Proteins 0.000 description 1
- 101001060252 Homo sapiens Fibulin-5 Proteins 0.000 description 1
- 101000839060 Homo sapiens Hemicentin-1 Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101000983166 Homo sapiens Phospholipase A2 group V Proteins 0.000 description 1
- 101001132674 Homo sapiens Retina and anterior neural fold homeobox protein 2 Proteins 0.000 description 1
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 description 1
- 101000716933 Homo sapiens Sterile alpha motif domain-containing protein 11 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000805941 Homo sapiens Usherin Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101000863415 Kluyveromyces lactis (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-1140 / WM37) 40S ribosomal protein S14 Proteins 0.000 description 1
- 206010023642 Lacrimation decreased Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108091007780 MiR-122 Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 102000004364 Myogenin Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 101150045883 POMGNT1 gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102100026832 Phospholipase A2 group V Human genes 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100036226 Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100033908 Retina and anterior neural fold homeobox protein 2 Human genes 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101000729661 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S8-A Proteins 0.000 description 1
- 101000635513 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S8-B Proteins 0.000 description 1
- 201000006760 Senior-Loken syndrome Diseases 0.000 description 1
- 102100021119 Serine protease HTRA1 Human genes 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 108091007415 Small Cajal body-specific RNA Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 102100020927 Sterile alpha motif domain-containing protein 11 Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 102000017299 Synapsin-1 Human genes 0.000 description 1
- 108050005241 Synapsin-1 Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 108091007416 X-inactive specific transcript Proteins 0.000 description 1
- 108091035715 XIST (gene) Proteins 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 108700013125 Zolgensma Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 108010070626 acid beta-galactosidase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 201000002543 age related macular degeneration 2 Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 208000025261 autosomal dominant disease Diseases 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 201000009507 autosomal recessive limb-girdle muscular dystrophy type 2O Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 102200042638 c.1358G>A Human genes 0.000 description 1
- 102220354899 c.1441G>C Human genes 0.000 description 1
- 102220419728 c.1500A>T Human genes 0.000 description 1
- 102220413977 c.1664C>T Human genes 0.000 description 1
- 102220354180 c.1664C>T Human genes 0.000 description 1
- 102220419205 c.1712C>T Human genes 0.000 description 1
- 102220414740 c.1737A>G Human genes 0.000 description 1
- 102220360931 c.3691A>G Human genes 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 208000003904 cone-rod dystrophy 3 Diseases 0.000 description 1
- 208000014455 congenital muscular dystrophy-dystroglycanopathy type A3 Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000027720 dry mucous membrane Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000017723 hereditary motor and sensory neuropathy type 6 Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 108091051828 miR-122 stem-loop Proteins 0.000 description 1
- 108091041042 miR-18 stem-loop Proteins 0.000 description 1
- 108091062221 miR-18a stem-loop Proteins 0.000 description 1
- 108091028067 miR-19b-1 stem-loop Proteins 0.000 description 1
- 108091046255 miR-8a stem-loop Proteins 0.000 description 1
- 108091028159 miR-92a-1 stem-loop Proteins 0.000 description 1
- 108091007426 microRNA precursor Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229950009805 onasemnogene abeparvovec Drugs 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 201000010680 retinitis pigmentosa 19 Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220234408 rs1114167611 Human genes 0.000 description 1
- 102220236111 rs1131691934 Human genes 0.000 description 1
- 102200132001 rs1135402744 Human genes 0.000 description 1
- 102200119884 rs119103214 Human genes 0.000 description 1
- 102200120522 rs121912519 Human genes 0.000 description 1
- 102220324924 rs138734772 Human genes 0.000 description 1
- 102220277289 rs1553412768 Human genes 0.000 description 1
- 102220277580 rs1553662861 Human genes 0.000 description 1
- 102220300987 rs1554081754 Human genes 0.000 description 1
- 102220286747 rs1554558484 Human genes 0.000 description 1
- 102220327838 rs1555591722 Human genes 0.000 description 1
- 102220094018 rs201798163 Human genes 0.000 description 1
- 102200126331 rs28937571 Human genes 0.000 description 1
- 102220056826 rs368482358 Human genes 0.000 description 1
- 102200163429 rs369088781 Human genes 0.000 description 1
- 102220135453 rs369488860 Human genes 0.000 description 1
- 102220240190 rs375064450 Human genes 0.000 description 1
- 102220041311 rs587778722 Human genes 0.000 description 1
- 102220039319 rs587780542 Human genes 0.000 description 1
- 102220201815 rs587780589 Human genes 0.000 description 1
- 102220013766 rs61731179 Human genes 0.000 description 1
- 102200028480 rs61753980 Human genes 0.000 description 1
- 102220026213 rs63749971 Human genes 0.000 description 1
- 102220085877 rs63750059 Human genes 0.000 description 1
- 102220286378 rs63751393 Human genes 0.000 description 1
- 102220057565 rs730881233 Human genes 0.000 description 1
- 102220100312 rs755193751 Human genes 0.000 description 1
- 102220062944 rs755395180 Human genes 0.000 description 1
- 102220219522 rs756197350 Human genes 0.000 description 1
- 102220059095 rs762396230 Human genes 0.000 description 1
- 102220279291 rs764616982 Human genes 0.000 description 1
- 102220086638 rs766438395 Human genes 0.000 description 1
- 102220322048 rs766438395 Human genes 0.000 description 1
- 102220264786 rs772460728 Human genes 0.000 description 1
- 102220059815 rs774324419 Human genes 0.000 description 1
- 102220083173 rs863224635 Human genes 0.000 description 1
- 102220095438 rs876658180 Human genes 0.000 description 1
- 102220096219 rs876659201 Human genes 0.000 description 1
- 102220122123 rs886043008 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000011096 spinal cancer Diseases 0.000 description 1
- 208000014618 spinal cord cancer Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Definitions
- Adeno-associated virus as a vector AAV is a single-stranded DNA parvovirus, the genome of which comprises the rep gene and the cap gene flanked by two inverted terminal repeats (ITRs) .
- the rep gene encodes, from a single ORF, Rep78, Rep68, Rep52 and Rep40, which aid AAV genome replication and virion assembly.
- Three capsid proteins (VP1, VP2 and VP3) are generated from a single cap ORF but are regulated by transcription from a rare start codon (ACG) and alternative splicing. As a result, VP1 and VP2 have the same amino acids as VP3 in their C-terminus.
- assembly-activating protein which is essential for capsid assembly, is encoded from an in-frame shifted ORF within the cap gene.
- All AAV virions are composed of 60 VP subunits at a 1: 1: 10 ratio of VP1: VP2: VP3.
- VP3 assembly-activating protein
- Comparison of the AAV VP3 structure among various serotypes has revealed highly homologous sequences interspersed with more evolutionary divergent areas. These amino acid stretches are commonly designated as variable regions (VRs) I through IX.
- VRs are localized at the surface of the assembled capsid and are assumed to be responsible for the capsid interaction with cell surface receptors and other host factors. Because of their location, VRs are also predicted to be less critical for capsid assembly. Therefore, the guiding principle of the capsid’s design to obtain novel AAV vectors was to modify only surface VRs while keeping the backbone sequence unchanged to maintain the integrity of the assembling scaffold.
- rAAV Recombinant adeno-associated viruses
- rAAVs are vectors used for in vivo gene transfer to carry out gene therapies and facilitate the gene transfer critical for a wide variety of basic science studies and clinical gene therapies.
- rAAVs Several characteristics make rAAVs attractive as gene delivery vehicles: (i) they provide long-term transgene expression, (ii) they are not associated with any known human disease, (iii) they elicit relatively weak immune responses, (iv) they are capable of transducing a variety of dividing and non-dividing cell types and (v) the rAAV genome can be packaged into a variety of capsids, or protein coat of the virus, which have different transduction characteristics and tissue tropisms.
- rAAV-gene based therapy has been successful in pre-clinical models in a variety of diseases including Rett syndrome, congenital ALS, Parkinson's , Huntington's disease and so on.
- AAV vectors constitute valuable gene delivery tools, there is still a strong demand for the development of improved AAVs.
- the successful use of rAAVs for the treatment of diseases and for scientific studies has been constrained by the lack of capsid serotypes that can efficiently transduce certain difficult cell types or tissues. And AAV vectors with greater transduction efficacy are always required to help patients get desired therapeutic effects with the lowest drug dose.
- One aspect of the invention provides a modified adeno-associated virus (mAAV) capsid protein comprising a retargeting peptide of SEQ ID NO: 4 inserted into, and/or substituting one or more residues of, a wild-type adeno-associated virus (AAV) capsid protein at any one of subdomains IV-VIII of the GH loop of the wild-type AAV capsid protein.
- mAAV modified adeno-associated virus
- the retargeting peptide is inserted into, and/or substitutes said one or more residues of subdomain VIII of GH loop.
- the retargeting peptide is inserted into and substitutes two residues corresponding to wild-type AAV9 VP1 capsid protein residues A587 and Q588.
- the retargeting peptide comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 1.
- the retargeting peptide comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 2.
- the retargeting peptide comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 3.
- the wild-type adeno-associated virus (AAV) capsid protein is AAV9 VP1, AAV9 VP2, or AAV9 VP3.
- the mAAV capsid protein further comprises one or more additional mutation (s) other than the incorporated retargeting peptide.
- mAAV modified adeno-associated virus
- capsid protein comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 25.
- mAAV modified adeno-associated virus
- capsid protein comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 26.
- mAAV modified adeno-associated virus
- capsid protein comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 27.
- Another aspect of the invention provides a recombinant adeno-associated virus (rAAV) viral particle, comprising a polynucleotide encapsidated within a capsid shell comprising an mAAV capsid polypeptide of the invention.
- rAAV adeno-associated virus
- the polynucleotide comprises a gene of interest (GOI) flanked by a 5’ ITR, a 3’ ITR, or both.
- GOI gene of interest
- the gene of interest is (a) a nucleic acid sequence encoding a trophic factor, a growth factor, or a soluble protein; (b) a cDNA that restores protein function to humans or animals harboring a genetic mutation (s) in that gene; (c) a cDNA that encodes a protein that can be used to control or alter the activity or state of a cell; (d) a cDNA that encodes a protein or a nucleic acid used for assessing the state of a cell; (e) a cDNA and/or associated guide RNA for performing genomic engineering; (f) a sequence for genome editing via homologous recombination; (g) a DNA sequence encoding a therapeutic RNA; (h) a shRNA or an artificial miRNA delivery system; and/or (i) a DNA sequence that influences the splicing of an endogenous gene.
- the gene of interest is: RPE65, REP1, LRAT, GRP143, TYR, BEST1, MERTK, MYO7A, ADAM9, RGR, RS1, CEP290, RPGR, BBS4, USH2D, RPGRIP, TULP1, CRB1, GUCY2D, AIPL1, CRX, ABCA4, PDE6B, RHO, PRPH2, NR2E3, NRL, CNGA3, CNGB3, GNAT2, PDE6C, RLBP1, ND4, or an agent that antagonize the function /expression thereof.
- the gene of interest is operatively linked to a transcriptional regulatory cassette comprising a promoter, such as a constitutive promoter, or a retina specific promoter (e.g., a promoter from GFAP, RLBP1, ProB2, Human RHO, RHOK, GRK1, Human blue opsin HB570, Human blue opsin HB569, PR0.5, PR1.7, PR2.1, 3LCR-PR0.5, hIRBP, IRBPe/GNAT2, CAR/ARR3, Crx2kb, ProA1, ProA4, ProC1, mGrm6, ProB4, Cabp5, Human red opsin, G1.7p, hRPE65p, NA65p, VMD2, or RS1) , and optionally an enhancer that modulates transcription from the constitutive promoter or the retina specific promoter.
- a promoter such as a constitutive promoter, or a retina specific promoter
- a retina specific promoter e.g., a promoter from GFAP, RL
- the gene of interest is: apolipoprotein E (ApoE) , apoE2, survival motor neuron 1 (SMN1) , acid alpha-glucosidase (GAA) , battenin, aspartoacylase protein (ASPA) , Aromatic L-amino acid decarboxylase (AADC) , lysosomal tripeptidyl peptidase I (TPP1) , lysosomal acid ⁇ -galactosidase ( ⁇ gal) , N-sulfoglycosamine sulfohydrolase (SGSH) , alpha-N-acetylglucosaminidase (NAGLU) , iduronate 2-sulfatase (IDS) , NPC1, frataxin (FXN) , gigaxonin, Glial cell line-derived neurotrophic factor (GDNF) , CLN6 Transmembrane ER Protein, alpha-Apoprotein
- the gene of interest is operatively linked to a transcriptional regulatory cassette, such as a constitutive promoter, or a CNS specific promoter (e.g., a promoter from Syn1, NSE, GFAP, MAG, MBP, F4/80, CD68, PAG, vGLUT, or GAD) , and optionally an enhancer that modulates transcription from the constitutive promoter or the CNS-specific promoter.
- a transcriptional regulatory cassette such as a constitutive promoter, or a CNS specific promoter (e.g., a promoter from Syn1, NSE, GFAP, MAG, MBP, F4/80, CD68, PAG, vGLUT, or GAD)
- a CNS specific promoter e.g., a promoter from Syn1, NSE, GFAP, MAG, MBP, F4/80, CD68, PAG, vGLUT, or GAD
- an enhancer that modulates transcription from the constitutive promoter or the CNS-specific promote
- the encapsidated polynucleotide further comprises: 1) an enhancer; 2) an intron or an exon that promotes the expression of the GOI; 3) a WPRE sequence; 4) a 5’ UTR coding sequence; 5) a 3’ UTR coding sequence; 6) an miRNA detargeting sequence; and/or 7) a polyA signal sequence.
- Another aspect of the invention provides a polynucleotide encoding the modified adeno-associated virus (mAAV) capsid protein of the invention, a polynucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity thereof.
- mAAV modified adeno-associated virus
- the polynucleotide is codon-optimized for mammalian expression.
- Another aspect of the invention provides a vector comprising the polynucleotide of the invention.
- the vector is a plasmid or a viral vector (e.g., HSV or baculovirus vector) .
- Another aspect of the invention provides a host cell comprising the modified adeno-associated virus (mAAV) capsid protein of the invention, the rAAV viral particle of the invention, the polynucleotide of the invention, or the vector of the invention.
- mAAV modified adeno-associated virus
- Another aspect of the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the modified adeno-associated virus (mAAV) capsid protein of the invention, the rAAV viral particle of the invention, the polynucleotide of the invention, or the vector of the invention.
- mAAV modified adeno-associated virus
- Another aspect of the invention provides a method of treating a ocular disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the rAAV of the invention.
- the gene of interest of the rAAV when compared to an otherwise identical reference rAAV with wild type AAV9 capsid, is preferentially expressed in a retinal cell.
- the retinal cell is selected from the group consisting of: a photoreceptor (e.g., a rod cell; a cone cell) , a retinal ganglion cell (RGC) , a muller cell (amuller glial cell) , a bipolar cell, an amacrine cell, a horizontal cell, or a retinal pigment epithelium (RPE) cell.
- a photoreceptor e.g., a rod cell; a cone cell
- RRC retinal ganglion cell
- a muller cell amuller glial cell
- bipolar cell e.g., an amacrine cell
- amacrine cell e.g., a amacrine cell
- horizontal cell e.g., a horizontal cell
- RPE retinal pigment epithelium
- the ocular disease or disorder is one or more selected from the group consisting of dry eye syndrome (e.g., DES, Chronic dry eye, Keratitis sicca; Xerophthalmia; Keratoconjunctivitis sicca) , Sjogren's syndrome, uveitis, noninfectious uveitis, anterior uveitis (iritis) , chorioretinitis, posterior uveitis, conjunctivitis, allergic conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC) , atopic keratoconjunctivitis, systemic immune mediated diseases such as cicatrizing conjunctivitis and other autoimmune disorders of the ocular surface, blepharitis, scleritis, age-related macular degeneration (AMD) , diabetic retinopathy (DR) , diabetic
- Another aspect of the invention provides a method of treating a central nervous system (CNS) disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the rAAV of the invention.
- CNS central nervous system
- the gene of interest of the rAAV when compared to an otherwise identical reference rAAV with wild type AAV9 capsid, is preferentially expressed in a CNS cell.
- the CNS cell is selected from the group consisting of: a neuron, a glial cell, and a vascular cell.
- the CNS disease or disorder is selected from the group consisting of: brain or spinal cord injury, Bell's palsy, cervical spondylosis, carpal tunnel syndrome, brain or spinal cord tumors, peripheral neuropathy, Guillain-Barré syndrome, headache, epilepsy, dizziness, and neuralgia.
- Another aspect of the invention provides a method of producing rAAV, wherein the rAAV comprises the mAAV capsid protein of the invention, the method comprising introducing an rAAV vector encoding a gene of interest to a producing or packaging cell line expressing the mAAV capsid protein of the invention.
- the producing or packaging cell line is infected with a vector encoding the mAAV capsid protein of the invention.
- the producer or packaging cell line is HEK293, HEK293T, A549, sf9 (insect cells) , or HeLa cells.
- Another aspect of the invention provides a retargeting peptide comprising, consisting essentially of, or consisting of SEQ ID NO: 4, such as any one of SEQ ID NOs: 1-3.
- the retargeting peptide when incorporated into subdomain VIII of the GH loop of the VP1, VP2, and/or VP3 capsid protein of AAV9, confers tropism for retinal tissues /cells and CNS.
- FIG. 1A Schematic diagram of the capsid variants of the invention.
- FIG. 1B Amino acid sequence of the inserted peptides in the capsid variants.
- FIG. 2A Fluorescence microscopic evaluation of tdTomato expression in cross sections of the retinal tissue 4 weeks after intravitreal injection.
- FIG. 2B Fluorescence microscopic evaluation of tdTomato expression in cross sections of the retinal tissue 4 weeks after intravitreal injection.
- RPE retinal pigment epithelial
- ONL outer nuclear layer
- INL inner nuclear layer
- GCL layer of ganglion cells.
- FIG. 3A Fluorescence microscopic evaluation of tdTomato expression in cross sections of the retinal tissue 4 weeks after subretinal injection.
- FIG. 3B Fluorescence microscopic evaluation of tdTomato expression in cross sections of the retinal tissue 4 weeks after subretinal injection.
- RPE retinal pigment epithelial
- ONL outer nuclear layer
- INL inner nuclear layer
- GCL layer of ganglion cells.
- FIG. 4A Fluorescence microscopic evaluation of tdTomato expression in sagittal sections of the brain 4 weeks after intrathecal injection.
- FIG. 4B Fluorescence microscopic evaluation of tdTomato expression in transverse sections of the spine cord 4 weeks after intrathecal injection.
- FIG. 5 shows a multi-sequence alignment of AAV1-AAV13 VP1 capsids, including the conserved domains and variable sequences within the GH loop (about 230 amino acids, located between the ⁇ G and ⁇ H strands) , including subdomains IV-VIII of the GH loop.
- Sequences 1-14 are AAV9 (SEQ ID NO: 15) , AAV1 (SEQ ID NO: 6) , AAV2 (SEQ ID NO: 7) , AAV3A (SEQ ID NO: 8) , AAV3B (SEQ ID NO: 9) , AAV4 (SEQ ID NO: 10) , AAV5 (SEQ ID NO: 11) , AAV6 (SEQ ID NO: 12) , AAV7 (SEQ ID NO: 13) , AAV8 (SEQ ID NO: 14) , AAV10 (SEQ ID NO: 16) , AAV11 (SEQ ID NO: 17) , AAV12 (SEQ ID NO: 18) , and AAV13 (SEQ ID NO: 19) .
- Consensus sequence is SEQ ID NO: 5.
- FIG. 6 shows a phylogenetic tree of the various Clades of AAV capsids.
- the invention described herein provides modified AAV capsids with altered tropism compared to the wild-type AAV9 capsid from which the modified capsids derive, and a recombinant AAV (rAAV) viral particle comprising an AAV viral capsid shell comprising such modified AAV capsid proteins.
- rAAV recombinant AAV
- the invention is partly based on the surprising discovery that certain retargeting peptides of the invention can be inserted into and/or substituting certain residues of the wild-type AAV sequences, particularly sequences within the GH loop, including GH loop subdomains IV-VIII (e.g., subdomain VIII) , to alter tropism.
- certain retargeting peptides of the invention can be inserted into and/or substituting certain residues of the wild-type AAV sequences, particularly sequences within the GH loop, including GH loop subdomains IV-VIII (e.g., subdomain VIII) , to alter tropism.
- substitution of two residues in subdomain VIII of the GH loop in the wild-type AAV9 capsid -which corresponds to residues A587 and Q588 of the wild-type AAV9 VP1 capsid protein -with any one of several subject retargeting peptides led to altered tropism of the wt AAV9, with enhanced tropism towards tissues such as retina and CNS.
- AAV viral vectors comprising such modified AAV capsids may be used to enhance delivery of any gene of interest to the retina or CNS as a target tissue, using any suitable delivery means (such as transduction via intravitreal injection or subretinal injection to the retina, and transduction via lumbar puncture-intrathecal injection to the CNS) .
- the rAAV viral particles of the invention can be used to deliver a DNA (e.g., single-stranded DNA) or RNA nucleic acid comprising any transgene or gene of interest (GOI) of suitable length (e.g., within the packaging limit of the various AAVs) to a host cell compatible with the tropism of the AAV capsid shell.
- a DNA e.g., single-stranded DNA
- RNA nucleic acid comprising any transgene or gene of interest (GOI) of suitable length (e.g., within the packaging limit of the various AAVs)
- a host cell compatible with the tropism of the AAV capsid shell.
- the rAAV vectors are referred to herein as AAV vectors or rAAV vectors.
- AAV or rAAV vectors can comprise DNA or RNA viral genetic material.
- One aspect of the invention provides a retargeting peptide that, when incorporated into an AAV capsid, such as in subdomain IV or VIII of the GH loop of the VP1, VP2, and/or VP3 of the AAV capsid (e.g., AAV9) , confers tropism for retinal tissues /cells and CNS.
- an AAV capsid such as in subdomain IV or VIII of the GH loop of the VP1, VP2, and/or VP3 of the AAV capsid (e.g., AAV9) , confers tropism for retinal tissues /cells and CNS.
- the retargeting peptide of the invention is about 6-14 residues in length. In certain embodiments, the retargeting peptide of the invention is about 6 residues in length. In certain embodiments, the retargeting peptide of the invention is about 7 residues in length. In certain embodiments, the retargeting peptide of the invention is about 8 residues in length. In certain embodiments, the retargeting peptide of the invention is about 9 residues in length. In certain embodiments, the retargeting peptide of the invention is about 10 residues in length. In certain embodiments, the retargeting peptide of the invention is about 11 residues in length.
- the retargeting peptide of the invention is about 12 residues in length. In certain embodiments, the retargeting peptide of the invention is about 13 residues in length. In certain embodiments, the retargeting peptide of the invention is about 14 residues in length.
- the retargeting peptide of the invention is about 9 or 10 residues in length, and is represented by Formula I:
- X1-X10 each represent an amino acid as defined below; optionally, one of X2-X6, such as X5 or X6, may be absent (e.g., X5 may be absent, or X6 may be absent, but both are not absent) ;
- X1 is D, E, N or Q, e.g., D or E;
- X2 is A, G, S, T, L, I, V, or absent, e.g., A, S, T or G (such as A or G) ;
- X3 is T, S, P, A, G, or absent, e.g., T or S;
- X4 is V, L, I, G, A, or absent, e.g., V, L, or I;
- X5 is A, G, S, T, L, I, V, or absent, e.g., A, S, T, or G (such as A or G) ;
- X6 is A, G, S, T, L, V, or absent, e.g., A, S, T, or G (e.g., A or G) ;
- X7 is V, L, I, G or A, e.g., V, L, or I;
- X8 is F, Y, or P, e.g., F or P;
- X9 is F, Y, or P, e.g., F or P;
- X10 is K, R, H, N, or Q, e.g., K, R, or H (such as K or R) .
- the retargeting peptide of SEQ ID NO: 4 when the retargeting peptide of SEQ ID NO: 4 is inserted into an AAV capsid, it is flanked by up to 4 residues (e.g., L1 and L2 N-terminal to X1, and/or L3-L4 C-terminal to X10) , wherein L1-L4 can independently either be naturally present in the AAV capsids, or are not naturally present in the wt AAV capsid.
- L1 and L2 N-terminal to X1, and/or L3-L4 C-terminal to X10 residues
- L1-L4 can independently either be naturally present in the AAV capsids, or are not naturally present in the wt AAV capsid.
- L1-L4 each represents an optional linker amino acid that together flank the retargeting peptide sequences at the N-terminal (L1 and L2) and/or the C-terminal end (L3 and L4) .
- each of L1, L2, L3 and L4, if present, is independently any amino acids.
- each of L1-L4 is independently selected from A, Q, L, I, V, G, S and T.
- each of L1-L4 is independently selected from A, Q, G and S.
- L1-L2 are /correspond to AAV9 VP1 residues Q585-S586 or A587-Q588, and/or L3-L4 are /correspond to AAV9 VP1 residues A589-Q590
- the retargeting peptide comprises, consisting essentially of, or consists of SEQ ID NO: 1 (EATVGLFPK) .
- the retargeting peptide comprises, consisting essentially of, or consists of SEQ ID NO: 2 (EATLAAVFPK) .
- the retargeting peptide comprises, consisting essentially of, or consists of SEQ ID NO: 3 (EATLGIFPK) .
- tropism-altering or retargeting peptides of the invention can be inserted into various wild-type AAV capsids (such as wild-type AAV9 capsids) to alter their tropism.
- AAV serotypes known in the art such as the one listed in the section above, share considerable degrees of sequence and structural similarity, such that the tropism-altering or retargeting peptides of the invention can be inserted into AAV capsids other than the wild-type AAV9 capsids as illustrated herein, and lead to altered tropism of these modified non-AAV9-based capsids.
- the X-ray crystallography structure of one of the first AAV capsids –AAV2 VP1 – was resolved at 3A resolution in 2002 (Xie, Proc. Natl. Acad. Sci. USA. 99: 10405-10410, 2002) , and provided the crucial knowledge to facilitate further retargeting modifications of AAV2 and the other serotypes.
- amino acid sequence alignments of AAV2 the canine parvovirus whose crystal structure was previously determined (Tsao, Science 251: 1456-1464, 1991)
- the other AAV serotypes as well as other neutralizing antibody binding data such as epitope mapping and mutagenesis, together have provided a wealth of information about certain surface-displayed domains and regions in AAV capsids that interfere with primary receptor binding, thus serving as a general guide to positioning insertions of foreign epitopes.
- Xie (supra) noted that there are striking similarities and differences among the crystal structures of AAV2 and the other crystallized parvoviruses.
- the core of all parvoviruses shares the ⁇ -barrel motif, consisting of anti-parallel ⁇ -sheets.
- sequence identity of the motif between autonomous and dependoviruses is low, these motifs can be superimposed, suggesting a high degree of functional similarity.
- the ⁇ -sheets that make up the barrel motif of AAV serotypes all share a high level of sequence identity.
- the looped-out domains between the ⁇ -sheets generally have less overall identity, with the longest loop located between ⁇ -sheets G and H (or the so-called “GH loop” ) .
- This GH loop is approximately 230 amino acids in length for the AAV serotypes, as well as many autonomous parvoviruses (Chapman and Rossmann, Structure, sequence, and function correlations among parvoviruses. Virology 194: 491-508, 1993) , and occupies greater than one-third of the total structure.
- the size of the GH loop although similar between AAV serotypes and autonomous parvoviruses, is the most divergent of any sequence in the capsid. This low homology at the amino acid level is reflected in surface topology differences and in epitopes for receptor binding.
- AAV2 has three clusters of three peaks centered about, and separated by about the 3-fold axis of symmetry of the AAV2 capsid.
- the peaks create a pocket with a diameter of
- the sequences that compose these structures are all from the GH loop.
- Similar structures were also found in Aleutian mink disease parvovirus and the insect densovirus which has 96 fewer amino acids in its GH loop.
- the retargeting peptide of the invention can be inserted into or substituting one or more residues in a variable region or a subdomain inside the GH-loop of the respective AAV wild-type capsids, such as subdomain IV, V, VI, VII, or VIII of the GH loop of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective clades to which these AAV capsids belong (see FIG. 6) .
- AAV9, together with AAVhu31 and AAVhu32 belong to Clade F.
- AAV capsid VP1 protein sequences including those of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, AAV PHP.
- eB, Anc80L65, Anc80L65AAP, and 7m8, are provided below.
- AAV1 SEQ ID NO: 6, see line 2 in FIG. 5.
- AAV2 SEQ ID NO: 7, see line 3 in FIG. 5.
- AAV3A SEQ ID NO: 8, see line 4 in FIG. 5.
- AAV3B SEQ ID NO: 9, see line 5 in FIG. 5.
- AAV4 SEQ ID NO: 10, see line 6 in FIG. 5.
- AAV5 SEQ ID NO: 11, see line 7 in FIG. 5.
- AAV6 SEQ ID NO: 12, see line 8 in FIG. 5.
- AAV7 SEQ ID NO: 13, see line 9 in FIG. 5.
- AAV8 SEQ ID NO: 14, see line 10 in FIG. 5.
- AAV9 SEQ ID NO: 15, see line 1 in FIG. 5.
- AAV10 SEQ ID NO: 16, see line 11 in FIG. 5.
- AAV11 SEQ ID NO: 17, see line 12 in FIG. 5.
- AAV12 SEQ ID NO: 18, see line 13 in FIG. 5.
- AAV-DJ SEQ ID NO: 20.
- AAV-PHP. eB SEQ ID NO: 21.
- Anc80L65 SEQ ID NO: 22.
- Selected capsid sequences are aligned using MUSCLE (MUltiple Sequence Comparison by Log-Expectation) , an online tool available from the EMBL-EBI website using the default parameters, and the results, including consensus sequence, are shown in FIG. 5.
- MUSCLE MUltiple Sequence Comparison by Log-Expectation
- the ⁇ G and ⁇ H beta-sheets, and the GH loop sequences in between, of the representative AAV capsids (AAV1-AAV13) , as well as subdomains IV-VIII of these capsids, are labeled in FIG. 5 accordingly.
- subdomains IV comprises, consists essentially of, or consists of a stretch of AAV capsid residues, the first (i.e., the most N-terminal residue of the stretch) of which is immediately C terminal to the residue corresponding to AAV9 VP1 residue I451, and the last (i.e., the most C-terminal residue of the stretch) of which is immediately N terminal to the residue corresponding to AAV9 VP1 residue L461.
- the stretch of AAV1 capsid residues in subdomain IV includes residues N451 –D460 of AAV1 VP1
- the stretch of AAV9 capsid residues in subdomain IV includes residues N452 –T460 of AAV9 VP1.
- subdomains V comprises, consists essentially of, or consists of a stretch of AAV capsid residues, the first (i.e., the most N-terminal residue of the stretch) of which is immediately C terminal to the residue corresponding to AAV9 VP1 residue Q487, and the last (i.e., the most C-terminal residue of the stretch) of which is immediately N terminal to the residue corresponding to AAV9 VP1 residue A506. That is, the stretch of AAV9 capsid residues in subdomain V includes residues R488 –G505 of AAV9 VP1.
- subdomains VI comprises, consists essentially of, or consists of a stretch of AAV capsid residues, the first (i.e., the most N-terminal residue of the stretch) of which is immediately C terminal to the residue corresponding to AAV9 VP1 residue S526, and the last (i.e., the most C-terminal residue of the stretch) of which is immediately N terminal to the residue corresponding to AAV9 VP1 residue S540. That is, the stretch of AAV9 capsid residues in subdomain VI includes residues H527 –G539 of AAV9 VP1.
- subdomains VII comprises, consists essentially of, or consists of a stretch of AAV capsid residues, the first (i.e., the most N-terminal residue of the stretch) of which is immediately C terminal to the residue corresponding to AAV9 VP1 residue G544, and the last (i.e., the most C-terminal residue of the stretch) of which is immediately N terminal to the residue corresponding to AAV9 VP1 residue M559. That is, the stretch of AAV9 capsid residues in subdomain VII includes residues K545 –V558 of AAV9 VP1.
- subdomains VIII comprises, consists essentially of, or consists of a stretch of AAV capsid residues, the first (i.e., the most N-terminal residue of the stretch) of which is immediately C terminal to the residue corresponding to AAV9 VP1 residue V580, and the last (i.e., the most C-terminal residue of the stretch) of which is immediately N terminal to the residue corresponding to AAV9 VP1 residue G594. That is, the stretch of AAV9 capsid residues in subdomain VIII includes residues A581 –T593 of AAV9 VP1.
- the retargeting peptide of the invention can be inserted into or substituting one or more residues in subdomain IV (corresponding to residues N452 –T460 of AAV9 VP1) of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain IV of AAV9.
- residues in subdomain IV corresponding to residues N452 –T460 of AAV9 VP1 of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain IV of AAV9.
- the retargeting peptide of the invention can be inserted into or substituting one or more residues in subdomain V (corresponding to residues R488 –G505 of AAV9 VP1) of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain V of AAV9.
- residues in subdomain V corresponding to residues R488 –G505 of AAV9 VP1 of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain V of AAV9.
- the retargeting peptide of the invention can be inserted into or substituting one or more residues in subdomain VI (corresponding to residues H527 –G539 of AAV9 VP1) of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain VI of AAV9.
- residues in subdomain VI corresponding to residues H527 –G539 of AAV9 VP1 of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain VI of AAV9.
- the retargeting peptide of the invention can be inserted into or substituting one or more residues in subdomain VII (corresponding to residues K545 –V558 of AAV9 VP1) of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain VII of AAV9.
- residues in subdomain VII corresponding to residues K545 –V558 of AAV9 VP1 of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain VII of AAV9.
- the retargeting peptide of the invention can be inserted into or substituting one or more residues in subdomain VIII (corresponding to residues A581 – T593, or S586-A589 of AAV9 VP1) of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsids belong, such as subdomain VIII of AAV9.
- subdomain VIII corresponding to residues A581 – T593, or S586-A589 of AAV9 VP1 of any of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and the related AAV capsids in the respective Clades to which these AAV capsi
- Another aspect of the invention provides a recombinant or modified adeno-associated virus (mAAV) capsid protein comprising a retargeting peptide of SEQ ID NO: 4 inserted into, and/or substituting one or more residues of, a wild-type adeno-associated virus (AAV) capsid protein at any one of subdomains IV-VIII of the GH loop of the wild-type AAV capsid protein.
- mAAV modified adeno-associated virus
- the retargeting peptide is inserted into, and/or substitutes the one or more residues of subdomain IV of GH loop. In certain embodiments, the retargeting peptide is inserted into, and/or substitutes the one or more residues of subdomain V of GH loop. In certain embodiments, the retargeting peptide is inserted into, and/or substitutes the one or more residues of subdomain VI of GH loop. In certain embodiments, the retargeting peptide is inserted into, and/or substitutes the one or more residues of subdomain VII of GH loop. In certain embodiments, the retargeting peptide is inserted into, and/or substitutes the one or more residues of subdomain VIII of GH loop.
- the retargeting peptide is inserted into and substitutes two residues corresponding to wild-type AAV9 VP1 capsid protein residues A587 and Q588.
- the retargeting peptide comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 1 (EATVGLFPK) .
- the retargeting peptide comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 2 (EATLAAVFPK) .
- the retargeting peptide comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 3 (EATLGIFPK) .
- a related aspect of the invention provides a modified adeno-associated virus (mAAV) capsid protein comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 25.
- a related aspect of the invention provides a modified adeno-associated virus (mAAV) capsid protein comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 26.
- a related aspect of the invention provides a modified adeno-associated virus (mAAV) capsid protein comprises, consists essentially of, or consists of the polypeptide of SEQ ID NO: 27.
- Protein sequences of the above representative recombinant AAV9 VP1 based capsids are provided below (peptide insertion bold italics) .
- the VP1 capsid protein is from AAV9.
- a recombinant VP1 capsid protein comprising a retargeting peptide insertion comprising 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids.
- the recombinant VP1 comprises a deletion comprising 1, 2, 3, 4, or 5 amino acids.
- substitution of the residues corresponding to A587 and Q588 of wt AAV9 VP1 is by any one of the amino acids sequences such as EATVGLFPK (SEQ ID NO: 1) , EATLAAVFPK (SEQ ID NO: 2) , or EATLGIFPK (SEQ ID NO: 3) .
- the substitution is by any one of the amino acids sequences has no more than 1, 2, 3, 4, or 5 changes (e.g., conserved substitutions) compared to any one of SEQ ID NOs: 1-3.
- the peptide insertion is after S586 (AAV9 VP1 numbering) .
- amino acids A587 and Q588 are deleted.
- the mAAV capsid protein further comprises one or more additional mutation (s) other than the incorporated retargeting peptide.
- the mAAV is based on or derived from wild-type AAV9 capsid, such as AAV9 VP1.
- the modified capsid is otherwise identical to wt AAV VP1 (e.g., wt AAV9 VP1) capsid protein, except for the substitution of residues corresponding to wt AAV9 VP1 residues A587 and Q588 with SEQ ID NO: 4 (such as any one of SEQ ID NOs: 1-3) .
- the modified AAV capsid protein further comprises one or more changes (e.g., addition, deletion, and/or substitution) in residues other than the substitution corresponding to wt AAV9 VP1 residues A587 and Q588, such that the modified AAV capsid is at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%identical to the corresponding wt AAV VP1 capsid outside the residues corresponding to wt AAV9 VP1 residues A587 and Q588 (i.e., in residues 1-586 and 589
- the modified AAV capsid protein further comprises no more than 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 amino acid sequence differences compared to wt AAV VP1, other than the substitution corresponding to wt AAV9 VP1 residues A587 and Q588 by SEQ ID NO: 4 (such as any one of SEQ ID NOs: 1-3) .
- amino acid sequence difference can be assessed by aligning the sequences of the modified AAV capsid with that of the wt AAV (e.g., AAV9) VP1, and count each difference (substitution, deletion and addition) in the sequence alignment as one difference.
- the mAAV is based on or derived from wild-type AAV capsid VP2, such as wt AAV9 capsid VP2, which corresponds to residues 138-736 of wt AAV9 VP1.
- residue 1 of wt AAV9 VP2 corresponds to residue 138 of wt AAV9 VP1
- residues A450 and Q451 of VP2 correspond to residues A587 and Q588 of VP1, respectively.
- the modified capsid is otherwise identical to wt AAV VP2 (e.g., wt AAV9 VP2) capsid protein, except for the substitution corresponding to wt AAV9 VP2 residues A450 and Q451 with SEQ ID NO: 4 (such as any one of SEQ ID NOs: 1-3) .
- the modified AAV capsid protein further comprising one or more changes (e.g., addition, deletion, and/or substitution) in residues other than those corresponding to wt AAV9 VP2 A450 and Q451, such that the modified AAV capsid is at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%identical to the corresponding wt AAV VP2 capsid outside the substituted residues corresponding to wt AAV9 VP2 residues A450 and Q451 (i.e., in residues 1-449 and 452-599 of wt AAV9 VP2) .
- the modified AAV capsid protein further comprises no more than 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 amino acid sequence differences compared to the corresponding wt AAV VP2, other than the substitution of residues corresponding to wt AAV9 VP2 residues A450 and Q451 by SEQ ID NO: 4 (such as any one of SEQ ID NOs: 1-3) .
- amino acid sequence difference can be assessed by aligning the sequences of the modified AAV capsid with that of the wt AAV (e.g., AAV9) VP2, and count each difference (substitution, deletion and addition) in the sequence alignment as one difference.
- the mAAV is based on or derived from wild-type AAV capsid VP3, such as wild-type AAV9 capsid VP3, which corresponds to residues 203-736 of wt AAV9 VP1.
- wild-type AAV9 capsid VP3 corresponds to residue 203 of AAV9 VP1
- residues A385 and Q386 of VP3 correspond to residues A587 and Q588 of VP1, respectively.
- the modified capsid is otherwise identical to wt AAV VP3 capsid protein, except for the substitution of residues corresponding to wt AAV9 VP3 residues A385 and Q386 with SEQ ID NO: 4 (such as any one of SEQ ID NOs: 1-3) .
- the modified AAV capsid protein further comprising one or more changes (e.g., addition, deletion, and/or substitution) in residues other than the substituted residues corresponding to wt AAV9 VP3 residues A385 and Q386, such that the modified AAV capsid is at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%identical to the corresponding wt AAV VP3 capsid outside the substituted residues corresponding to wt AAV9 VP3 residues A385 and Q386 (i.e., in residues 1-384 and 387-534 of wt AAV9 VP3) .
- one or more changes e.g., addition, deletion, and/or substitution in residues other than the substituted residues corresponding to wt AAV9 VP3 residues A385 and Q386, such that the
- the modified AAV capsid protein further comprises no more than 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 amino acid sequence differences compared to the corresponding wt AAV VP3, other than the substitution of residues corresponding to wt AAV9 VP3 residues A385 and Q386 by SEQ ID NO: 4 (such as any one of SEQ ID NOs: 1-3) .
- amino acid sequence difference can be assessed by aligning the sequences of the modified AAV capsid with that of the wt AAV (e.g., AAV9) VP3, and count each difference (substitution, deletion and addition) in the sequence alignment as one difference.
- rAAV adeno-associated virus
- AAV or rAAV viral particle includes viral particles comprising a polynucleotide encapsidated within a capsid shell comprising any one or more modified AAV capsid proteins of the invention.
- the capsid shell may consists of only the subject modified AAV capsids, or may comprise the subject modified AAV capsids as well as any other wild-type or engineered capsids of any adeno-associated virus (AAV) (such as those belonging to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae) .
- AAV adeno-associated virus
- the capsid shell comprises a modified AAV (e.g., AAV9) VP1 capsid as described herein.
- the capsid shell may further comprise wt AAV (e.g., AAV9) VP1, VP2, and/or VP3.
- the capsid shell comprises a modified AAV (e.g., AAV9) VP2 capsid as described herein.
- the capsid shell may further comprise wt AAV (e.g., AAV9) VP1, VP2, and/or VP3.
- the capsid shell comprises a modified AAV (e.g., AAV9) VP3 capsid as described herein.
- the capsid shell may further comprise wt AAV (e.g., AAV9) VP1, VP2, and/or VP3.
- the capsid shell comprises a modified AAV (e.g., AAV9) VP1 capsid and a modified AAV (e.g., AAV9) VP2 capsid as described herein.
- the capsid shell may further comprise wt AAV (e.g., AAV9) VP1, VP2, and/or VP3.
- the capsid shell comprises a modified AAV (e.g., AAV9) VP2 capsid and a modified AAV (e.g., AAV9) VP3 capsid as described herein.
- the capsid shell may further comprise wt AAV (e.g., AAV9) VP1, VP2, and/or VP3.
- the capsid shell comprises a modified AAV (e.g., AAV9) VP1 capsid and a modified AAV (e.g., AAV9) VP3 capsid as described herein.
- the capsid shell may further comprise wt AAV (e.g., AAV9) VP1, VP2, and/or VP3.
- the capsid shell comprises a modified AAV (e.g., AAV9) VP1 capsid, a modified AAV (e.g., AAV9) VP2 capsid, and a modified AAV (e.g., AAV9) VP3 capsid as described herein.
- the capsid shell may further comprise wt AAV (e.g., AAV9) VP1, VP2, and/or VP3.
- the capsid shell may further comprise one or more additional VP capsid (s) from non-AAV9 AAV capsid (s) , or non-AAV9 parvoviral capsids.
- the polynucleotide comprises a gene of interest (GOI) flanked by a 5’ ITR and a 3’ ITR, or one of the ITR’s.
- the GOI (such as a ssDNA or ssRNA) is linked to a 3’ ITR (but not a 5’ ITR) .
- the ITR refers to an RNA sequence.
- the 5’ ITR, the 3’ ITR, or both ITR’s may be from AAV9, a non-AAV9 AAV (such as AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh10, AAVpo. 1, AAV12 etc.
- the 5’ ITR may be from AAV2 (or AAV9) .
- the 3’ ITR may be from AAV2 (or AAV9) .
- both the 5’ and 3’ ITR’s are from AAV2 (or AAV9) .
- the 5’ ITR, the 3’ ITR, or both are wild-type ITR sequences.
- one or both ITR’s are modified ITR sequences that may have a mutation, e.g., a deletion, such as a 5’ deletion in the 5’ ITR, or a 3’ deletion in the 3’ ITR, or an internal deletion, so long as the modified ITR contains a functional RBE (Rep binding element) sequence.
- the modified ITR contains the RBE sequence, a small palindrome that comprises a single tip of an internal hairpin within the terminal repeat (or RBE’ sequence) , and the trs (terminal resolution site) .
- the GOI can be any gene (s) or coding sequence (s) , including coding sequence for a protein or polypeptide, or a non-protein product, such as any non-translated RNA or non-coding RNA (ncRNA, such as siRNA, piRNA, short hairpin RNA or shRNA, microRNA or miRNA or precursors thereof including pre-miRNA and pri-miRNA, antisense sequence or oligonucleotide (ASO) , guide RNA or gRNA for CRISPR/Cas, rRNA, tRNA, snoRNA, snRNA, exRNA, scaRNA, lncRNA, Xist, and HOTAIR, ribozyme, aptamer, or other functional polynucleotide that does not encode protein.
- ncRNA non-coding RNA
- ASO antisense sequence or oligonucleotide
- guide RNA or gRNA for CRISPR/Cas rRNA,
- the GOI is (a) a nucleic acid sequence encoding a trophic factor, a growth factor, or a soluble protein; (b) a cDNA that restores protein function to humans or animals harboring a genetic mutation (s) in that gene; (c) a cDNA that encodes a protein that can be used to control or alter the activity or state of a cell; (d) a cDNA that encodes a protein or a nucleic acid used for assessing the state of a cell; (e) a cDNA and/or associated guide RNA for performing genomic engineering; (f) a sequence for genome editing via homologous recombination; (g) a DNA sequence encoding a therapeutic RNA; (h) a shRNA or an artificial miRNA delivery system; and/or (i) a DNA sequence that influences the splicing of an endogenous gene.
- the AAV viral vector encapsidated within the modified AAV capsid of the invention comprises a GOI that encodes a protein or polypeptide that remedies a gene defective in a target cell (to be infected by the AAV) , wherein expression of the GOI in the target cell remedies the defect.
- a target cell having a null or partial loss-of-function mutation in the gene such that the lack of the gene product by the gene is causative of the defect in the target cell, and that expression of the GOI partially or completely restores the function of the gene to remedy the defect.
- the AAV viral vector encapsidated within the modified AAV capsid of the invention comprises a GOI that encodes an antagonizing agent that remedies a defect in a target cell (to be infected by the AAV) , wherein expression of the antagonizing agent /GOI in the target cell remedies the defect.
- a target cell having a deleterious mutation e.g., dominant gain-of-function mutation, presence of a wild-type or mutant gene causative of the defect, duplication or other large scale genomic defects, etc.
- the antagonizing agent can be any of an RNAi reagent (e.g., siRNA, shRNA, miRNA) , antisense oligonucleotides (ASOs) , ZFN, TALEN or CRISPR/Cas systems that targets one or more disease genes, DNA-or RNA-base editors for gene editing, encoded neutralizing antibodies or antigen-binding fragments thereof, etc.
- RNAi reagent e.g., siRNA, shRNA, miRNA
- ASOs antisense oligonucleotides
- ZFN ZFN
- TALEN TALEN
- CRISPR/Cas systems that targets one or more disease genes
- DNA-or RNA-base editors for gene editing encoded neutralizing antibodies or antigen-binding fragments thereof, etc.
- the GOI effects gene addition /gene replacement. In certain embodiments, the GOI effects gene knockdown /knockout. In certain embodiments, the GOI effects gene correction (e.g., using DNA-base editing) . In certain embodiments, the GOI effects RNA correction (e.g., using RNA base editing) . In certain embodiments, the GOI effects gene-expression correction (e.g., using ASO or CRISPR etc to modulate transcripts splicing) .
- the transcript of the coding sequence or the gene of interest may be further processed inside the cell (e.g., pre-or pri-miRNA may be further processed after transcription to become miRNA, mRNA may be spliced) .
- Processing of the transcript or an RNA coding sequence can produce one or more RNA products, such as siRNA, miRNA, and/or mRNA, which may be further translated into protein product (s) , or be incorporated into other cellular machinery such as the RISC complex or a CRISPR/Cas effector enzyme (such as a Class 2, type II, V, or VI effector enzyme) .
- the GOI may comprise one or more introns between exons.
- the GOI corresponds to a cDNA (e.g., without unspliced intron) .
- the GOI comprises one coding sequence. In certain embodiments, the GOI comprises more than one (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) coding sequences. In certain embodiments, the GOI comprises two or more coding sequences encoding identical or different products (such as light chain and heavy chain of an antibody, a protein and a non-coding polynucleotide, two functionally related or complementary products, etc) .
- the length of the coding sequence of the GOI, or the combined length of all coding sequences of the GOI, is no more than the maximum length of DNA or RNA that can be packaged into a particular or chosen AAV viral particle, which can differ from one specific AAV viral particle from another.
- the packaging capacity of the AAV is about 4.7 kb, or between 4.3-5.2 kb.
- the protein can be any protein of interest, including enzymes, structural proteins, membrane proteins, cytokines, antibodies or antigen-binding fragments thereof, G proteins, GPCRs, kinases, transcription factors, etc.
- the GOI encodes a product for treating an ocular disease or disorder, such as an inherited retinal dystrophies (IRD) , Retinitis Pigmentosa (RP) , Choroideremia, Stargardt disease, Cone-rod Dystrophy (CRD) , Leber Congenital Amaurosis (LCA) .
- an ocular disease or disorder such as an inherited retinal dystrophies (IRD) , Retinitis Pigmentosa (RP) , Choroideremia, Stargardt disease, Cone-rod Dystrophy (CRD) , Leber Congenital Amaurosis (LCA) .
- the ocular disease or disorder is due to or caused by an autosomal recessive mutation
- the GOI encodes a gene product that remedies the autosomal recessive mutation (e.g., the GOI encodes a wide type gene that is the subject of the autosomal recessive mutation) .
- the ocular disease or disorder is due to or caused by an autosomal dominant mutation
- the GOI encodes a gene product that remedies the autosomal dominant mutation (e.g., the GOI encodes an antagonist of the mutant, such as a CRISPR/Cas effector and a guide RNA, or an RNAi reagent or antisense that specifically targeting the mutant gene or transcript) .
- the ocular disease or disorder is due to or caused by an X-linked mutation
- the GOI encodes a gene product that remedies the X-linked mutation
- the GOI encodes a product for treating a neuronal /CNS disease or disorder.
- the GOI is codon optimized for optimal expression in a target tissue.
- the target tissue is a mammalian tissue, such as human tissue.
- the GOI is under the transcriptional control of a promoter, and optionally an enhancer that modulates (e.g., enhances) the transcription from the promoter.
- an enhancer that modulates (e.g., enhances) the transcription from the promoter.
- Exemplary non-limiting promoters include: constitutive promoters, tissue-specific promoters, inducible promoters, temperature sensitive promoters, etc. Exemplary promoters and enhancers are described herein below (incorporated by reference) .
- the promoter is specific for an ocular tissue, such as a retina specific promoter.
- the promoter is specific for a CNS tissue, such as a neuronal specific promoter, or a glial cell (such as astrocyte) specific promoter.
- the polynucleotide comprising the GOI further comprises an intron and/or an exon that enhances expression of the GOI.
- intron refers to a non-coding segment of a DNA or an RNA, which are normally removed a transcribed RNA through splicing.
- the polynucleotide sequence of the invention may comprise an intron sequence, such as an intron sequence from a heterologous gene ( “heterologous” with respect to the gene of interest or GOI, which is to be expressed as a transgene delivered to a host cell by the rAAV viral particle of the invention) , in order to enhance the expression of the GOI.
- heterologous with respect to the gene of interest or GOI, which is to be expressed as a transgene delivered to a host cell by the rAAV viral particle of the invention
- Such intron sequence in the RNA sequence of the invention may or may not be removed by splicing.
- such intron sequence may further comprise a transcribed enhancer or a part thereof, since certain enhancers can be located within an intron of a coding DNA.
- exon refers to a coding segment of a DNA or an RNA, which exon is to be translated into a protein sequence.
- an exon sequence within the polynucleotide sequence of the invention may encode part of or the entirety of the GOI to be expressed as a transgene delivered to a host cell by the rAAV viral particle of the invention.
- an exon sequence within the polynucleotide sequence of the invention may belong to a heterologous gene (with respect to the GOI) , and the presence of such exon may enhance the expression of the GOI.
- the polynucleotide comprising the GOI further comprises a polyA signal sequence.
- exemplary polyA signals and sequences are described herein below (incorporated by reference) .
- the polynucleotide comprising the GOI further comprises a 5’ UTR region, a 3’ UTR region, or both. Exemplary UTR’s are described herein below (incorporated by reference) .
- the polynucleotide comprising the GOI further comprises a filler sequence.
- Another aspect of the invention provides a polynucleotide encoding any one of the modified capsid protein of the invention.
- Another aspect of the invention provides a vector comprising the polynucleotide of the invention.
- the vector is a plasmid, or a viral vector such as AdV, HSV or baculovirus vector designed for AAV production.
- Another aspect of the invention provides a method of treating or preventing an ocular disease or disorder in a subject in need thereof, the method comprising administering to (the eye (s) of) the subject a therapeutically effective amount of the rAAV of the invention, or an rAAV comprising any one of the modified AAV capsid of the invention.
- treating may include preventing a disease, disorder or condition from occurring in a cell, a tissue, a system, animal or human which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; stabilizing a disease, disorder or condition, e.g., arresting its development; and/or relieving one or more symptoms of the disease, disorder or condition, e.g., causing regression of the disease, disorder and/or condition.
- the treatment is not preventive-only treatment, and/or not prophylactic-only treatment (e.g., treatment excludes preventive or prophylactic treatment) .
- a therapeutic that “prevents” a disorder or condition refers to a treatment that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
- the gene of interest of /encoded by the rAAV is preferentially expressed in a retinal cell wherein compared to an otherwise identical reference rAAV with wild type AAV9 capsids.
- the retinal cell is selected from the group consisting of: a photoreceptor (e.g., a rod cell; or a cone cell) , a retinal ganglion cell (RGC) , a muller cell (amuller glial cell) , a bipolar cell, an amacrine cell, a horizontal cell, or a retinal pigment epithelium (RPE) cell.
- a photoreceptor e.g., a rod cell; or a cone cell
- RRC retinal ganglion cell
- a muller cell amuller glial cell
- bipolar cell e.g., an amacrine cell
- amacrine cell e.g., a amacrine cell
- horizontal cell e.g., a horizontal cell
- RPE retinal pigment epithelium
- the ocular disease or disorder is one or more selected from the group consisting of dry eye syndrome (e.g., DES, Chronic dry eye, Keratitis sicca; Xerophthalmia; Keratoconjunctivitis sicca) , Sjogren's syndrome, uveitis, noninfectious uveitis, anterior uveitis (iritis) , chorioretinitis, posterior uveitis, conjunctivitis, allergic conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC) , atopic keratoconjunctivitis, systemic immune mediated diseases such as cicatrizing conjunctivitis and other autoimmune disorders of the ocular surface, blepharitis, scleritis, age-related macular degeneration (AMD) , diabetic retinopathy (DR) , diabetic
- Another aspect of the invention provides a method of treating a central nervous system (CNS) disease or disorder in a subject in need thereof, the method comprising administering to (the CNS of) the subject a therapeutically effective amount of the rAAV of the invention, or an rAAV comprising any one of the modified AAV capsid of the invention.
- CNS central nervous system
- the gene of interest of the rAAV is preferentially expressed in a CNS cell compared to an otherwise identical reference rAAV with wild type AAV9 capsids.
- the CNS cell is selected from the group consisting of: a neuron, a glial cell, and a vascular cell.
- the CNS disease or disorder is selected from the group consisting of: brain or spinal cord injury, Bell's palsy, cervical spondylosis, carpal tunnel syndrome, brain or spinal cord tumors, peripheral neuropathy, Guillain-Barré syndrome, headache, epilepsy, dizziness, and neuralgia.
- Another aspect of the invention provides a method of producing rAAV comprising a modified AAV capsid protein of the invention, the method comprising introducing an rAAV vector encoding a gene of interest to a producer or packaging cell line expressing the modified AAV capsid protein of the invention, under conditions suitable to package the GOI into an AAV capsid shell comprising the modified AAV capsid protein of the invention.
- the producer or packaging cell line is infected with a vector encoding the modified AAV capsid protein of the invention.
- the producer or packaging cell line is HEK293, HEK293T, sf9(insect cells) , A549, or HeLa cells.
- the subject viral particles comprising the modified AAV capsids of the invention can be used to encapsidate any polynucleotide sequences having at least one ITR sequence, such as the 5’ ITR, the 3’ ITR, or both.
- the ITR sequences can be derived from any known ITR sequences of the various AAV serotypes in the art, including any natural or recombinant AAV serotypes.
- Exemplary non-limiting ITR sequences can be, or can be derived from any one of the following AAV serotypes: AAV1, AAV10, AAV106.1/hu. 37, AAV11, AAV114.3/hu. 40, AAV 12, AAV127.2/hu. 41, AAV127.5/hu. 42, AAV128.1/hu. 43, AAV128.3/hu. 44, AAV130.4/hu. 48, AAV145.1/hu. 53, AAV145.5/hu. 54, AAV145.6/hu. 55, AAV16.12/hu. l 1, AAV16.3, AAV16.8/hu. 10, AAV161.10/hu. 60, AAV161.6/hu.
- AAV5 AAV52.1/hu. 20, AAV52/hu. 19, AAV5-22/rh. 58, AAV5-3/rh. 57, AAV54.1/hu. 21, AAV54.2/hu. 22, AAV54.4R/hu. 27, AAV54.5/hu. 23, AAV54.7 /hu.24, AAV58.2/hu. 25, AAV6, AAV6.1, AAV6.1.2, AAV6.2, AAV7, AAV7.2, AAV7.3/hu.
- AAV8 AAV-8b, AAV-8h, AAV9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV A3.3, AAV A3.4, AAV A3.5, AAV A3.7, AAV-b, AAVC1, AAVC2, AAVC5, AAVCh. 5, AAVCh. 5R1, AAVcy. 2, AAVcy. 3, AAVcy. 4, AAVcy. 5, AAVCy. 5Rl, AAVCy. 5R2, AAVCy. 5R3, AAVCy. 5R4, AAVcy.
- AAVhu. l AAVhu. 12, AAVhu. 13, AAVhu. 14/9, AAVhu. 15, AAVhu. 16, AAVhu. 17, AAVhu. 18, AAVhu. 19, AAVhu. 2, AAVhu. 20, AAVhu. 21, AAVhu. 22, AAVhu. 23.2, AAVhu. 24, AAVhu. 25, AAVhu. 27, AAVhu. 28, AAVhu. 29, AAVhu. 29R, AAVhu. 3, AAVhu. 31, AAVhu. 32, AAVhu. 34, AAVhu. 35, AAVhu. 37, AAVhu. 39, AAVhu. 4, AAVhu.
- AAVLG-9/hu. 39 AAVLG-9/hu.
- AAVrh. 64R2 AAVrh. 65, AAVrh. 67, AAVrh. 68, AAVrh. 69, AAVrh. 70, AAVrh. 72, AAVrh. 73, AAVrh. 74, AAVrh. 8, AAVrh.
- AAVrh8R AAVrh8R A586R mutant, AAVrh8R R533A mutant, BAAV, BNP61 AAV, BNP62 AAV, BNP63 AAV, bovine AAV, caprine AAV, Japanese AAV 10, true type AAV (ttAAV) , UPENN AAV 10, AAV-LK16, AAAV, AAV Shuffle 100-1, AAV Shuffle 100-2, AAV Shuffle 100-3, AAV Shuffle 100-7, AAV Shuffle 10-2, AAV Shuffle 10-6, AAV Shuffle 10-8, AAV SM 100-10, AAV SM 100-3, AAV SM 10-1, AAV SM 10-2, and/or AAV SM 10-8.
- the modified AAV capsids of the invention in addition to the incorporation of SEQ ID NO: 4, such as substitution of residues corresponding to wt AAV9 VP1 capsid residues A587 and Q588, may comprise one or more additional changes.
- the modified AAV capsid of the invention may comprise a further change in the otherwise wt AAV9 sequence outside the substitution, such as the sequence changes described by Pulichla et al. (Molecular Therapy 19 (6) : 1070-1078, 2011) , or such as the changes in AAV9.9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84.
- a further change in the otherwise wt AAV9 sequence outside the substitution such as the sequence changes described by Pulichla et al. (Molecular Therapy 19 (6) : 1070-1078, 2011) , or such as the changes in AAV9.9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84.
- the modified AAV capsid of the invention may additionally comprise one or more changes in amino acids 390-627 (AAV9 VP1 numbering) as described by Pulichla et al. (Molecular Therapy 19 (6) : 1070-1078, 2011, incorporated herein by reference) .
- the additional changes may be, but are not limited to: AAV9.1 (G1594C; D532H) , AAV6.2 (T1418A and T1436X; V473D and I479K) , AAV9.3 (T1238A; F413Y) , AAV9.4 (T1250C and A1617T; F417S) , AAV9.5 (A1235G, A1314T, A1642G, C1760T; Q412R, T548A, A587V) , AAV9.6 (T1231A; F411I) , AAV9.9 (G1203A, G1785T, W595C) , AAV9.10 (A1500G, T1676C; M559T) , AAV9.11 (A1425T, A1702C, A1769T; T568P, Q590L) , AAV9.13 (A1369C, A1720T; N457H, T574S)
- the modified AAV capsid of the invention may additionally comprise a sequence change described in US 6,156,303, such as AAV3B (SEQ ID NOs: 1 and 10 of US 6,156,303) , AAV6 (SEQ ID NOs: 2, 7 and 11 of US 6,156,303) , AAV2 (SEQ ID NOs: 3 and 8 of US 6,156,303) , AAV3A (SEQ ID NOs: 4 and 9, of US 6,156,303) , or derivatives thereof.
- AAV3B SEQ ID NOs: 1 and 10 of US 6,156,303
- AAV6 SEQ ID NOs: 2, 7 and 11 of US 6,156,303
- AAV2 SEQ ID NOs: 3 and 8 of US 6,156,303
- AAV3A SEQ ID NOs: 4 and 9, of US 6,156,303
- the modified AAV capsid of the invention may additionally comprise features of AAV-DJ or a variant thereof, such as AAVDJ8 (or AAV-DJ8) , as described by Grimm et al. (Journal of Virology 82 (12) : 5887-5911, 2008) .
- the amino acid sequence of AAV-DJ8 may comprise two or more mutations in order to remove the heparin binding domain (HBD) .
- the AAV-DJ sequence described as SEQ ID NO: 1 in US 7, 588, 772 may comprise two mutations: (1) R587Q (Arg at amino acid 587 is changed to glutamine Gln) , and (2) R590T.
- the AAV-DJ like sequence changes may comprise one or more of the three mutations: (1) K406R, (2) R587Q, and (3) R590T.
- the modified AAV capsid of the invention may additionally comprise a sequence feature as described in WO2015/121501, such as in true type AAV (ttAAV) (SEQ ID NO: 2 of WO2015/121501) , in the so-called UPenn AAV10 (SEQ ID NO: 8 of WO2015/121501) , or in the so-called Japanese AAV10 (SEQ ID NO: 9 of WO2015/121501) , or variants thereof.
- ttAAV true type AAV
- UPenn AAV10 SEQ ID NO: 8 of WO2015/121501
- Japanese AAV10 SEQ ID NO: 9 of WO2015/121501
- modified AAV capsids of the invention can be used with any one or more AAV’s with different tropism to create hybrid capsid shells.
- Any one or more of the AAV serotypes described herein or above (see above, incorporated herein by reference) can be used with the modified AAV capsids for this purpose.
- the modified AAV capsids of the invention can be used in a hybrid capsid sequence derived from two or more capsids.
- AAV2G9 comprises sequences from AAV2 and AAV9. Any one or more of the AAV serotypes described herein or above (see Sec. 2 above, incorporated herein by reference) can be used with the modified AAV capsids for this purpose.
- the modified AAV capsid of the invention may additionally comprise at least one AAV capsid CD8 + T-cell epitope.
- the AAV may be AAV1, AAV2 or AAV8.
- the modified AAV capsid may additionally comprise features of PHP.
- a or PHP. B as described in Deverman (Nature Biotechnology. 34 (2) : 204-209, 2016, incorporated herein by reference) .
- the modified AAV capsid may additionally comprise features of a serotype generated by Cre-recombination-based AAV targeted evolution (CREATE) described by Deverman et al., (Nature Biotechnology 34 (2) : 204-209, 2016, incorporated herein by reference) .
- CREATE Cre-recombination-based AAV targeted evolution
- the AAV serotypes generated in this manner have improved CNS transduction and/or neuronal and astrocytic tropism, as compared to other AAV serotypes.
- the rAAV viral particles of the invention comprises a polynucleotide encoding a gene of interest (GOI) , and may further comprise additional optional sequence elements (such as expression control elements) that may enhance or regulate the expression of the GOI.
- GOI gene of interest
- additional optional sequence elements such as expression control elements
- Expression control elements present within the GOI-containing polynucleotide facilitate proper heterologous polynucleotide (e.g., GOI) transcription and/or translation, including, e.g., splicing signal for introns, maintenance of the correct reading frame of the gene to permit in-frame translation of mRNA and, stop codons etc.
- heterologous polynucleotide e.g., GOI
- expression control elements are nucleic acid sequence (s) , such as promoters and enhancers that influence expression of an operably linked heterologous polynucleotide (e.g., GOI) .
- s nucleic acid sequence
- Such elements typically act in cis but may also act in trans.
- Expression control can be effected at the level of transcription, translation, splicing, message stability, etc.
- an expression control element that modulates transcription is juxtaposed near the 5'end (i.e., “upstream” ) of the transcribed polynucleotide.
- Expression control elements can also be located at the 3'end (i.e., “downstream” ) of the transcribed sequence or within the transcript (e.g., in an intron) . Expression control elements can be located at a distance away from the transcribed gene of interest sequence (e.g., 100 to 500, 500 to 1000, 2,000 to 5,000, or more nucleotides from the gene of interest polynucleotide) . Nevertheless, owing to the polynucleotide length limitations for viral vectors, such as AAV vectors, such expression control elements will typically be within 1-1,000, 1-500, 1-250, or 1-100 nucleotides from the transcribed gene of interest sequence.
- Introns are known to possess a posttranscriptional regulatory element that efficiently induces transport of mRNA out of the nucleus and enhances mRNA stability.
- the GOI-containing polynucleotide includes one or more introns or a fragment thereof.
- the one or more introns are fragments of the gene of interest.
- the one or more introns are heterologous to the gene of interest.
- Introns have been reported to affect the levels of gene expression. This effect is known as Intron Mediated Enhancement (IME) of gene expression (Lu et al., Mol Genet Genomics 279: 563-572, 2008) .
- the levels of gene expression are increases by about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5 fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, or about 10-fold when compared to gene expression from a sequence without the one or more introns.
- Non-limiting introns include SV40 intron, beta globin intron, and short chimeric intron (CIB) .
- Other introns include the ColE2-RNA-OUT, OIPR, and R6K-RNA-OUT introns described in Lu et al., Hum Gene Ther. 2017; 28 (1) : 125-134 (incorporated by reference) ; the human hemoglobin subunit beta (HBB2) synthetic intron (Snyder et al., Hum Gene Ther, 8 (1997) , pp. 1891-1900, incorporated by reference) .
- HBB2 human hemoglobin subunit beta
- the one or more introns may be less than 25 nucleotides, less than 50 nucleotides, less than 100 nucleotides, less than 150 nucleotides, less than 200 nucleotides, less than 250 nucleotides, less than 300 nucleotides, less than 350 nucleotides, less than 400 nucleotides, less than 450 nucleotides, or less than 500 nucleotides.
- the one or more introns may be more than 25 nucleotides, more than 50 nucleotides, more than 100 nucleotides, more than 150 nucleotides, more than 200 nucleotides, more than 250 nucleotides, more than 300 nucleotides, more than 350 nucleotides, more than 400 nucleotides, more than 450 nucleotides, or more than 500 nucleotides.
- the one or more introns may be about 50 to about 100 nucleotides, about 50 to about 200 nucleotides, about 50 to about 300 nucleotides, about 50 to about 400 nucleotides, about 50 to about 500 nucleotides, about 100 to about 200 nucleotides, about 100 to about 300 nucleotides, about 100 to about 400 nucleotides, about 100 to about 500 nucleotides, about 200 to about 300 nucleotides, about 200 to about 400 nucleotides, about 200 to about 500 nucleotides, about 300 to about 400 nucleotides, about 300 to about 500 nucleotides, or about 400 to about 500 nucleotides.
- Enhancer can refer to a sequence that is located adjacent to the gene of interest. Enhancer elements are typically located upstream of a promoter element in the GOI-containing polynucleotide, but can also be located downstream of or within an intron sequence (e.g., a gene of interest) and remain functional. Thus the enhancer or part thereof may be present in a transcribed RNA sequence.
- Non-limiting examples of suitable enhancers include a CMV enhancer.
- an enhancer element can be located 100 base pairs, 200 base pairs, or 300 or more base pairs upstream or downstream of a gene of interest (e.g., in the RNA AAV vector or a DNA AAV vector) .
- Enhancer elements typically increase expressed of a gene of interest above increased expression afforded by a promoter element.
- UTRs refer to RNA that are not translated after transcription.
- the 5’ UTR is upstream of the start code of the gene of interest and the 3’ UTR is downstream of the stop codon of the gene of interest.
- the 5’ and/or 3’ UTRs may have an insertion, deletion, or modification to enhance stability of the transcribed gene of interest.
- the 5′UTR may comprise a translation initiation sequence such as, but not limited to, a Kozak sequence and an internal ribosome entry site (IRES) .
- Kozak sequences have the consensus CCR (A/G) CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG) , which is followed by another G.
- 3′UTRs are known to have stretches of Adenosines and Uridines embedded in them. These AU rich signatures are particularly prevalent in genes with high rates of turnover. Based on their sequence features and functional properties, the AU rich elements (AREs) can be separated into three classes (Chen et al, 1995) : Class I AREs contain several dispersed copies of an AUUUA motif within U-rich regions. C-Myc and MyoD contain class I AREs. Class II AREs possess two or more overlapping UUAUUUA (U/A) (U/A) nonamers. Molecules containing this type of AREs include GM-CSF and TNF-a. Class III ARES are less well defined.
- the 5’ UTR and/or 3’UTR may comprise heterologous sequence to the gene of interest. In some embodiments, the 5’ UTR and/or 3’ UTR are native to the gene of interest.
- a 5’ UTR and/or a 3’ UTR from an mRNA normally expressed in a specific tissue or organ such as lung, liver, pancreas, endothelial cells, CNS, neurons, astrocytes, skeletal muscle, cardiac muscle, smooth muscle, blood, hematopoietic cells may be used in the RNA sequence of the invention comprising a GOI targeted to one or more of these tissues.
- the DNA AAV vector or RNA AAV vector comprises a transcribed modified AAV ITR that is 5’ to a polyA sequence, a polyA signal sequence (e.g., AAUAAA) , or a sequence for RNA transcription termination (e.g., a histone downstream element) .
- polyA sequence ” “polyA tail, ” “polyA signal sequence, ” and “a sequence for RNA transcription termination” are defined herein above.
- Representative polyA signal sequence and surrounding sequences include human growth hormone (hGH) polyA sequence (see Liu et al., Gene Ther 20: 308–317, 2013, incorporated by reference) , bovine growth hormone polyadenylation signal (bGHpA) (Goodwin and Rottman, J Biol Chem. 1992 Aug 15; 267 (23) : 16330-4, incorporated by reference) , SV40 early or late polyadenylation signal, and the synthetic polyA signal used in Choi et al. (Mol Brain. 2014; 7: 17, incorporated herein by reference) .
- hGH human growth hormone
- bGHpA bovine growth hormone polyadenylation signal
- SV40 early or late polyadenylation signal SV40 early or late polyadenylation signal
- synthetic polyA signal used in Choi et al. (Mol Brain. 2014; 7: 17, incorporated herein by reference) .
- a “transcription enhancer” refer to cis-acting nucleotide sequences that can increase the transcription of the gene of interest.
- the transcription enhancer can be located in the intron or partially in an exon region of the GOI-containing polynucleotide of the invention.
- the GOI-containing polynucleotide of the invention comprises a transcribed WPRE sequence, encoded by the WPRE sequence on the encoding DNA.
- Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE) is a 600-bp or so DNA sequence that, when transcribed, creates a tertiary structure enhancing expression.
- WPRE is commonly used in molecular biology to increase expression of genes delivered by viral vectors. It is a tripartite regulatory element with gamma, alpha, and beta components.
- the alpha component is 80 bp long: GCCACGGCGGAACTCATCGCCGCC TGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGG T (SEQ ID NO: 30) .
- the alpha component is only 9%as active as the full tripartite WPRE sequence, which is 100%identical to base pairs 1093-1684 of the Woodchuck hepatitis B virus (WHV8) genome.
- the WPRE sequence or part thereof (such as the gamma, alpha, and beta elements, preferably in the given order) is present in a 3’ UTR region coding sequence of a GOI-containing polynucleotide encapsidated in the rAAV viral particle of the invention, to substantially increase stability and protein yield of the GOI-containing polynucleotide of the invention.
- the WPRE sequence is a shorted WPRE (WPRE2) containing a minimal gamma element and a partial alpha-beta element (see Kalev-Zylinska, J Neurosci. 2007, 27: 10456-10467, incorporated by reference) .
- the WPRE sequence is a shorted WPRE (WPRE3) containing minimal gamma and alpha elements (see Choi et al., Mol Brain 7, 17 (2014) , incorporated by reference) .
- the RNA sequence of the invention comprises a WPRE sequence and a GOI lacking introns.
- promoter as used herein is defined as a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence.
- the GOI-containing polynucleotide of the invention may comprise a promoter for transcribing the GOI.
- promoter/regulatory sequence means a nucleic acid sequence which is required for expression of a gene product operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence. In other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product.
- the promoter /regulatory sequence may, for example, be one which expresses the gene product (e.g., the RNA sequence of the invention) in a tissue or cell type specific manner.
- operable linkage or “operably linked” refers to a physical or functional juxtaposition of the components so described as to permit them to function in their intended manner.
- the relationship is such that the control element modulates expression of the heterologous polynucleotide.
- two DNA sequences operably linked means that the two DNAs are arranged (cis or trans) in such a relationship that at least one of the DNA sequences is able to exert a physiological effect upon the other sequence.
- the promoter is a constitutive promoter.
- a “constitutive” promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.
- exemplary promoter may include: a ⁇ glucuronidase (GUSB) promoter, a cytomegalovirus (CMV) immediate-early (Ie) enhancer and/or promoter, a chicken ⁇ -actin (CBA) promoter or derivative thereof such as a CAG promoter, CB promoter, a (human) elongation factor 1 ⁇ -subunit (EF1 ⁇ ) promoter, and a ubiquitin C (UBC) promoter.
- GUSB ⁇ glucuronidase
- CMV cytomegalovirus
- Ie immediate-early
- CBA chicken ⁇ -actin
- CAG promoter CAG promoter
- CB promoter CB promoter
- EF1 ⁇ elongation factor 1 ⁇ -subunit
- UBC ubiquitin C
- the promoter is an inducible promoter.
- an “inducible” promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell substantially only when an inducer which corresponds to the promoter is present in the cell.
- the promoter is a tissue-specific promoter, a species specific promoter, or a cell cycle-specific promoter. See Parr et al., Nat. Med. 3: 1145-9, 1997 (entire contents incorporated herein by reference) .
- tissue-or cell-type-specific promoter is a nucleotide sequence which, when operably linked with a polynucleotide encodes or specified by a gene, causes the gene product to be produced in a specific cell type or a specific tissue preferentially, due to, for example, the cell /tissue is a cell type or tissue type in which the promoter is normally active.
- Tissue-or cell type-specific promoters may include neuronal tissue specific promoter; CNS-or PNS-specific promoter such as astrocyte, oligodendrocyte, or neuronal promotor; hematopietic lineage specific promoter such as B cell promoter, T cell promoter, NK cell promoter, monocyte promoter, leukocyte promoter, macrophage promoter; endothelial cell promoter; pancreatic promoter; liver /hepatic cell promoter; lung tissue promoter, etc.
- CNS-or PNS-specific promoter such as astrocyte, oligodendrocyte, or neuronal promotor
- hematopietic lineage specific promoter such as B cell promoter, T cell promoter, NK cell promoter, monocyte promoter, leukocyte promoter, macrophage promoter
- endothelial cell promoter pancreatic promoter
- liver /hepatic cell promoter lung tissue promoter, etc.
- tissue-specific promoters include prion promoter, neuron-specific enolase (NSE) , neurofilament light (NFL) promoter, neurofilament heavy (NFH) promoter, platelet-derived growth factor (PDGF) , platelet-derived growth factor B-chain (PDGF- ⁇ ) , synapsin (Syn) , synapsin 1 (Syn1) , methyl-CpG binding protein 2 (MeCP2) , Ca2+/calmodulin-dependent protein kinase II (CaMKII) , metabotropic glutamate receptor 2 (mGluR2) , neurofilament light (NFL) or heavy (NFH) , ⁇ -globin minigene n ⁇ 2, preproenkephalin (PPE) , enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2) promoters.
- NSE neuron-specific enolase
- NSE neurofilament light
- Astrocyte-specific promoters include glial fibrillary acidic protein (GFAP) and EAAT2 promoters.
- Oligodendrocyte-specific promoters include the myelin basic protein (MBP) promoter.
- MBP myelin basic protein
- the promoter is a retina specific promoter. In certain embodiments, the promoter is a promoter from or derived from GFAP, RLBP1, ProB2, Human RHO, RHOK, GRK1, Human blue opsin HB570, Human blue opsin HB569, PR0.5, PR1.7, PR2.1, 3LCR-PR0.5, hIRBP, IRBPe/GNAT2, CAR/ARR3, Crx2kb, ProA1, ProA4, ProC1, mGrm6, ProB4, Cabp5, Human red opsin, G1.7p, hRPE65p, NA65p, VMD2, or RS1.
- the promoter is a CNS specific promoter. In certain embodiments, the promoter is a promoter from or derived from Syn1, NSE, GFAP, MAG, MBP, F4/80, CD68, PAG, vGLUT, or GAD.
- the promoter is heterologous to the gene of interest. In some embodiments, the promoter is the natural promoter of the gene of interest. In some embodiments, the heterologous promoter includes an insertion, deletion, substitution, and/or other mutation. In some embodiments, the natural promoter includes an insertion, deletion, substitution, and/or other mutation.
- the promoter is a Pol II promoter. In certain embodiments, the promoter is a Pol III promoter, such as H1 and U6 promoter.
- localized delivery of the AAV viral particles of the invention can preferentially deliver the AAV viral particle of the invention to specific target cells, tissues, or organs
- systemic delivery through, for example, intraveneous injection or other intravascular administration, can sometimes lead to infection of more or more non-target cells, tissue, or organs, and undesired expression of the transgene or gene-of-interest (GOI) carried by the AAV vector genome of the invention.
- GOI gene-of-interest
- the liver is a major target for many AAV vectors, even though liver expression of the transgene may not be desired for certain GOIs.
- undesired, and potentially toxic off-target transduction and transgene expression in non-target tissues or organs may include the CNS, skeletal muscle, heart, pancreas, and antigen-presenting cells (APCs) .
- APCs antigen-presenting cells
- Such undesired off-target transduction has led to a range of toxic side effects including thrombocytopenia, transaminitis, lethal hemorrhage and shock, anemia, renal failure, complement activation, neuron degeneration, acute elevations in liver enzymes and/or reductions in platelets.
- tissue or cell specific expression of the AAV viral particles of the invention can be partly controlled by the viral capsids of the AAV viral particles, as well as the tissue-or cell-specific promoters.
- tissue or cell-specific expression can be partly controlled by certain tissue detargeting sites or detargeting sequences present in the RNA transcript of the AAV vector genome of the invention.
- tissue detargeting site /sequence can prevent, suppress, or otherwise inhibit the expression of the GOI on the AAV vector genome of the invention, based on the expression of certain endogenous microRNAs (miRNAs) or controlled exogenous miRNA in the non-targeting tissue.
- the small, noncoding miRNAs generally regulate gene expression by post-transcriptional silencing through two mechanisms –by reducing target mRNA stability and/or protein expression (e.g., by two-to four fold or less) when partially complementary to a target mRNA sequence, or by cleaving the target mRNA and/or triggering its degradation when nearly perfectly complementary to the target mRNA.
- the AAV vector genome of the invention comprises coding sequence for a microRNA (miR) detargeting site /sequence, or a microRNA binding site series (miRBSS) , or a reverse complement thereof, wherein the miR binding site series comprise one, two, three, four, five, or more copies of a miR binding site (miRBS) .
- the miR binding site series comprise three copies of miR binding sites that maybe identical or different.
- the “miR binding site series” or the “miR binding site” includes an RNA sequence on the RNA transcript produced by transcribing the AAV vector genome.
- the “miR binding site series” or the “miR binding site” also includes the DNA sequence corresponding to the RNA sequence, in that they differ only by the T in DNA and the U in RNA.
- the reverse complement of such DNA is the coding sequence for the RNA sequence. That is, in certain embodiments, in an expression cassette containing a DNA positive strand, the miR binding site sequence is the reverse complement of the miRNA to which it binds.
- the miR binding site is substantially complementary to (e.g., is a reverse complement sequence of) a microRNA (miR) guide strand sequence, such as the guide strand sequence of a naturally existing miR inside a host cell, such that when the AAV vector genome is transcribed in the host cell infected by the AAV to produce an RNA transcript comprising the miR binding site or miR binding site series, the miR (e.g., naturally existing miR inside the host cell) can bind to the miR binding site or the miR binding site series to interfere with the expression of any transgene on the RNA transcript in the host cell.
- miR microRNA
- the miR binding site series or the miR binding site is located in the 3’-UTR region of a transgene (or gene of interest (GOI) ) transcript, before the polyA sequence.
- the miR binding site series or the miR binding site is located in the 5’-UTR region of the transgene.
- the miR binding site series or the miR binding site is located in both the 5’-and 3’-UTR region of the transgene.
- the AAV vector genome comprises coding sequence for at least two (e.g., three) miR binding sites located in the 5’ UTR, and at least two (e.g., three) miR binding sites located in the 3’ UTR.
- the start of the first of the at least one or more (e.g., three) miR binding site is within 20, 40, 60, 80, 100, 120 nucleotides from the 3’ end of the gene coding sequence or the beginning of the polyA sequence in the RNA transcript.
- the end of the last of the at least one or more (e.g., three) miR binding site is within 20, 40, 60, 80, 100, 120 nucleotides from the 5’ end of the gene coding sequence or the 5’ end of the GOI RNA transcript.
- each miR binding site is independently (designed to be) 100%identical, or nearly 100%identical (e.g., with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mismatches) to the miR in the host cell.
- the mismatched nucleotides are contiguous. In certain embodiments, the mismatched nucleotides are non-contiguous. In certain embodiments, the mismatched nucleotides occur outside the seed region-binding sequence of the miR binding site, such as at one or both ends of the miR binding site.
- each miR binding site is independently at least about 90%, 95%, 96%, 97%, 98%, or 99%identical, or nearly 100%identical to the miR in the host cell.
- the RNA transcript comprising the miR binding site upon binding to the miR in the host cell, is eventually cleaved and/or degraded, thus preventing /attenuating /eliminating the expression of any transgene on the RNA transcript.
- each miR binding site is independently exact complementarity (100%) , or partial complementarity to the miRNA seed sequence with some mismatches.
- each miR binding site independently comprises at least 7-8 nucleotides which are 100%complementary to the miRNA seed sequence.
- each miR binding site independently consists of a sequence which is 100%complementary to the miRNA seed sequence.
- each miR binding site series contains multiple copies (e.g., two or three copies) of the sequence which is 100%complementary to the seed sequence.
- the region of 100%complementarity comprises at least 30%of the length of each miR binding site sequence. In certain embodiments, the remainder of the miR binding site sequence has at least about 80%to about 99%complementarity to the miRNA.
- each miR binding site is independently (designed to be) somewhat identical to the miR in the host cell, such that the RNA transcript comprising the miR binding site binds to the miR in the host cell with reduced complementarity, and reduces (but does not completely) eliminate the expression of the transgene on the RNA transcript.
- the miRBSS comprises two or more copies of miR binding sites, such as three miR binding sites.
- the two or more copies of miR binding sites are in tandem, e.g., appear consecutively, or be separated by one or more nucleotides from each other or one another.
- the two or more copies of miR binding sites are identical in sequence.
- three miR binding sites can be identical in sequence.
- the miR binding site series comprises, consists essentially of, or consists of two copies of miR binding sites that are different in sequence.
- the miR binding site series comprises, consists essentially of, or consists of three copies of miR binding sites that are each different in sequence from the other.
- the miR binding site series comprises, consists essentially of, or consists of three copies of miR binding sites, two of which are identical in sequence while the third is different in sequence.
- the two miR binding sites with identical sequence can be in tandem, or be separated by the miR binding site with a different sequence.
- each of the miR binding site or sequence region may independently have a length such as, but not limited to, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112,
- each of the miR binding site or sequence region is independently at least about 7 to about 28 nucleotides in length, at least about 8 to about 28 nucleotides in length, 7-28 nucleotides, 8-18 nucleotides, 12-28 nucleotides, about 20 to about 26 nucleotides, about 22 nucleotides, about 24 nucleotides, or about 26 nucleotides in length, and which optionally contains at least one consecutive region (e.g., 7 or 8 nucleotides) which is complementary to the seed sequence of the miRNA (e.g., miR183) .
- the miR binding site is complementary to a miR expressed in a non-target tissue at a high copy number, such as more than 10,000 copies per cell, 20,000 copies per cell, 30,000 copies per cell, 40,000 copies per cell, 50,000 copies per cell, 60,000 copies per cell, 70,000 copies per cell, 80,000 copies per cell, or 100,000 copies or more per cell.
- the miR binding site is complementary to a miR expressed in heart and skeletal muscle, such as miR-1.
- the miR binding site is complementary to a miR expressed in liver or hepatocytes, such as miR122.
- the miR binding site is complementary to a miR expressed in hematopoietic lineage, including immune cells (e.g., antigen presenting cells or APC, including dendritic cells (DCs) , macrophages, and B-lymphocytes) , such as those described in US2018/0066279 (all incorporated herein by reference, especially Tables 1-3) , including miR-15a, miR-16-1, miR-17, miR-8a, miR-19a, miR-20a, miR-19b-l, miR-21, miR-29a, miR-29b, miR-29c, miR-30b, miR-31, miR-34a, miR-92a-l, miR-106a, miR-125a, miR-125b, miR-126, miR-142-3p (miR142) , miR-146a, miR-150, miR-155, miR-181a, miR-223 and miR-424.
- immune cells
- the miR binding site is complementary to an APC-specific miR expressed in APCs, such as dendritic cells (DCs) , such as miR-30b, miR-34a, miR-125a, miR-125b, miR-142-3p, and miR-155.
- APCs dendritic cells
- the miR binding site series comprises, consists essentially of, or consists of at least one miR binding site sequence for a hematopoietic lineage-specific miR.
- said at least one miR binding site sequence for a hematopoietic lineage-specific miR comprises, consists essentially of, or consists of a sequence at least 80%, 85%, 90%, at least 95%, at least 99%, or 100%identical to any one of the sequences in Table 2 of US2018/0066279 (incorporated herein by reference) .
- miR-15a Monocytes CD5 + B cells miR-16-1 Monocytes, CD5 + B cells miR-17 B-and T-cells, monocyte miR-18a B-and T-cells, monocyte miR-19a B-and T-cells, monocyte miR-20a B-and T-cells, monocyte miR-19b-1 B-and T-cells, monocyte miR-21 Myeloid cells miR-29a T-cells miR-29b T-cells miR-29c T-cells miR-30b DC (dendritic cells) miR-31 T-cells miR-34a DC, B-cells miR-92a-1 B-and T-cells, monocyte miR-106a Monocytes miR-125a B-cells, DC, monocytes miR-126 Endothelial cells, pDC miR-125b B-cells, DC, monocytes miR-142-3p Hematopoietic stem cells, T reg miR-146a Moncytes
- the miR binding site is complementary to a miR expressed in DRG (dorsal root ganglion) neurons, such as miR96, miR182, or miR183.
- the miR binding site series comprises, consists essentially of, or consists of at least one miR183 binding site sequence.
- the at least one miR183 binding site comprises, consists essentially of, or consists of a sequence at least 80%, 85%, 90%, at least 95%, at least 99%, or 100%identical to AGTGAATTCTACCA GTGCCAT A (SEQ ID NO: 28) , where the sequence complementary to the miR-183 seed sequence is double underlined.
- the miR binding site series comprises, consists essentially of, or consists of at least one miR182 binding site sequence.
- the at least one miR182 binding site comprises, consists essentially of, or consists of a sequence at least 80%, 85%, 90%, at least 95%, at least 99%, or 100%identical to AGTGTGAGTTCTACCATTGCCAAA (SEQ ID NO: 29) .
- the miR binding site series comprises, consists essentially of, or consists of at least one miR96 binding site sequence.
- the at least one miR96 binding site comprises, consists essentially of, or consists of a sequence at least 80%, 85%, 90%, at least 95%, at least 99%, or 100%identical to AGCAAAAATGTGCTAGTGCCAAA (SEQ ID NO: 30) .
- the miR binding site series comprises at least 1, 2, 3, 4, 5, or 6 miR183/182/96 binding site sequence (s) .
- the miR binding site series comprises two or more miR binding sites that may be identical or different. In certain embodiments, miR binding sites within the miR binding site series are continuous and not separated by spacer (s) .
- a “spacer” is generally any selected nucleic acid sequence of, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length, which is located between two or more consecutive miR binding site sequences.
- the spacer is a non-coding sequence of about 1 to about 12 nucleotides, or 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 nucleotide in length.
- a spacer is located 3’ to the first miR binding site sequence and/or 5’ to the last miR binding site sequence.
- the spacers between the miR binding sequences are the same when more than one spacers are present in the miR binding site series. In other embodiments, at least two spacers are different in sequence.
- the AAV vector genome of the invention comprises a miRBS that limits the expression of the GOI in RPE cells.
- miR binding sites for the RPE-specific miR-204 can block AAV-mediated gene expression in RPE cells, resulting in PR-specific expression.
- the AAV vector genome of the invention comprises one or more (e.g., 1, 2, 3, 4, 5, or 6) miR-204 binding site (s) that limits the expression of the GOI in RPE cells.
- the AAV vector genome of the invention comprises a miRBS that limits the expression of the GOI in PR.
- miR binding sites for the PR-specific miR-124 can block AAV-mediated gene expression in PR (photoreceptor) cells, resulting in RPE-specific expression.
- the AAV vector genome of the invention comprises one or more (e.g., 1, 2, 3, 4, 5, or 6) miR-124 binding site (s) that limits the expression of the GOI in PR cells.
- the rAAV viral particles of the invention can be used to deliver any gene of interest to any suitable target cell, tissue, or organism for any use for gene therapy.
- IRDs Inherited retinal dystrophies encompass a diverse group of blinding diseases affecting approximately 1 in 3,000 people. There is significant genotypic and phenotypic variability with over 300 genes and gene loci currently implicated in IRDs, with conditions inherited in autosomal recessive, autosomal dominant, or X-linked pattern. IRDs have become a major topic of medical interest after ground-breaking clinical trials led to the first ever FDA-approved in vivo gene product, voretigene neparvovec-rzyl also known as Luxturna. Ocular gene therapies for autosomal recessive diseases are rapidly expanding with improved efficiency in second generation viral vectors and additional developments being researched.
- gene editing and RNA modulation strategies are being evaluated to antagonize the deleterious effect of dominant mutations. These technologies will be especially important in treatment of autosomal dominant diseases.
- gene editing and RNA modulation strategies are not only useful for antagonizing the deleterious effect of dominant mutations, but also useful for large gene defect correction.
- DNA editing or DNA base editing
- gene expression correction e.g., by using CRISPR or antisense oligonucleotides (ASOs) to modulate transcripts splicing
- ASOs antisense oligonucleotides
- the modified AAV capsids and rAAV comprising the same may be used in the treatment of such ocular diseases in gene therapy.
- Transduction of retinal pigment epithelial (RPE) cells with an AAV based on serotype 2 has partially corrected retinal blindness in LCA2.
- RPE retinal pigment epithelial
- PR rod and cone photoreceptors
- the normal human retina contains two main classes of light-sensing neurons: rod PRs, which are sensitive to dim light, and cone PR, which respond to bright light stimuli. Gene mutations hinder the function of either or both of these sets of cells, and lead to their degeneration and subsequent loss of vision. Over 200 different genes/loci are implicated in these types of blinding disorders (see sph. uth. tmc. edu dot retnet dot disease dot htm) .
- the GOI of the invention to be encompassed by the AAV vector genome encapsidated with the modified AAV capsids of the invention includes any one of the known target genes responsible for any of the disorders listed in the above website, e.g., target genes the expression of which, as the GOI carried by the AAV vectors of the invention, alleviates at least one symptom of the disorders.
- the GOI of the invention to be encompassed by the AAV vector genome encapsidated with the modified AAV capsids of the invention includes an agent that antagonizes the function /expression of any one of the known target genes responsible for any of the disorders listed in the above website, e.g., target genes the expression of which is associated with or causative of at least one symptom of the disorders, and the down-regulation of the expression of which by the agent (that antagonizes the function /expression of the known target genes) alleviates at least one symptom of the disorders.
- antagonizing agents include any one or more of: ZFN, TALEN, or CRISPR system nucleases (that targets the dominant disease genes, and/or be used as tools for correcting genes or modulating gene expression) ; antibodies or antigen binding fragments thereof (that neutralize a gene product of the dominant disease genes, such as anti-VEGF antibody) ; RNAi reagents (siRNA, shRNA, miRNA etc) , antisense polynucleotides, or other non-coding polynucleotides (that down-regulate the expression of the dominant disease genes) , etc.
- target genes include any one or more of: RPE65, REP1, LRAT, GRP143, TYR, BEST1, MERTK, MYO7A, ADAM9, RGR, RS1, CEP290, RPGR, BBS4, USH2D, RPGRIP, TULP1, CRB1, GUCY2D, AIPL1, CRX, ABCA4, PDE6B, RHO, PRPH2, NR2E3, NRL, CNGA3, CNGB3, GNAT2, PDE6C, RLBP1, and ND4.
- Retinitis pigmentosa primarily affects rod PR but can result in secondary abnormalities of cones.
- Cone and cone-rod dystrophies such as Stargardt's disease are characterized by a primary cone involvement, with possibly concomitant loss of rods.
- Achromatopsia is associated with reduced or minimal cone function, and the complete form of this disorder is autosomal recessive in inheritance.
- Age-related macular degeneration affects rods and cones centrally in the retina due to atrophy of the retinal pigment epithelium.
- AAV2, AAV7 and AAV8 can efficiently transduce rods, only AAV9 targeted cones both centrally and peripherally efficiently at low doses, likely due to the abundance of galactosylated glycans, the primary receptor for AAV9, on cone PRs.
- AAV9 and derivatives with modified AAV capsids of the invention are ideal candidates for strategies that require restoration of cone PR function.
- AAV9 showed inferior long-term transduction stability in mouse retina via subretinal injection, it played a totally different pattern in non-human primates, AAV9 could not only target rods like other AAV serotypes but also target cones both centrally and peripherally efficiently at low doses 4 months after injection.
- AAV9 and derivatives with modified AAV capsids of the invention are ideal vectors for retina transduction especially in human.
- the rAAVs of the invention are administered locally, for ocular gene therapy.
- rAAV particles of the invention are administered to the subretinal space (i.e. a cavity that is formed after injection of liquids between the RPE and the PRs) .
- the rAAVs of the invention are administered into the eye's vitreous, resulting in transduction of cells within the inner retina, mainly of ganglion cells and muller glial cells.
- AAV serotypes Few of the naturally occurring AAV serotypes is capable of transducing PRs when administered intravitreally because of the physical barrier at the inner limiting membrane or the lack of appropriate receptors at the ILM. Each route of administration has its own advantages and disadvantages. Intravitreal injection is minimally invasive but leads to higher immune responses. Subretinal injection of rAAVs would help reduce immunogenicity of the product and less product is needed, however it is invasive.
- the rAAV viral particles of the invention can be used to deliver any gene of interest to any suitable target cell, tissue, or organism (such as an ocular tissue /cell or a CNS tissue or cell) , for any use for gene therapy to such suitable target cells, tissues, or organisms.
- a rAAV comprising the modified AAV capsids of the invention is administered to a subject in need thereof.
- the rAAV can be administered to treat ocular diseases or disorders.
- the rAAV is administered via intravitreal injection (i.e., by injecting the vector into the vitreous of the eye) or subretinal injection (i.e., by injecting the vector into the space between RPE cells and photoreceptors) .
- the ocular disease is one or more selected from the group consisting of dry eye syndrome (e.g., DES, Chronic dry eye, Keratitis sicca; Xerophthalmia; Keratoconjunctivitis sicca) , Sjogren's syndrome, uveitis, noninfectious uveitis, anterior uveitis (iritis) , chorioretinitis, posterior uveitis, conjunctivitis, allergic conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC) , atopic keratoconjunctivitis, systemic immune mediated diseases such as cicatrizing conjunctivitis and other autoimmune disorders of the ocular surface, blepharitis, scleritis, age-related macular degeneration (AMD) , diabetic retinopathy (DR) , diabetic macular
- the ocular disease is dry eye syndrome. In one embodiment, the ocular disease is allergic conjunctivitis. In one embodiment the ocular disease is age-related macular degeneration (AMD) . In one embodiment the ocular disease is diabetic retinopathy.
- AMD age-related macular degeneration
- ocular disease As used herein, the terms “ocular disease, ” “ocular condition, ” “eye disease, ” and “eye condition” refer to diseases/conditions of the eye (s) that can be sight threatening, lead to eye discomfort, and may signal systemic health problems.
- Dry eye syndrome (DES, Chronic dry eye, Keratitis sicca; Xerophthalmia; Keratoconjunctivitis sicca) can be defined as a condition that includes a variety of disorders that result in a loss of, or altered composition of, the natural tear film, which maintains the surface of the eye. Without this tear film, vision is impaired and patients may suffer severe ocular discomfort.
- DES can be caused by excessive tear evaporation or by a reduction of tear production in the lacrimal gland, which is the site of tear production. Though the exact causes of this condition are unknown, there is evidence supporting the link between reduced tear production and inflammation of one or more components of the lacrimal apparatus.
- DES may also be a manifestation of Sjogren's syndrome which is an autoimmune disorder in which the glands that produce tears and saliva are destroyed. This leads to dry mouth, decreased tearing, and other dry mucous membranes.
- Noninfectious uveitis is a chronic inflammatory, putative Th1/Th17-mediated autoimmune disease associated with substantial visual morbidity and is potentially blinding. Blindness from uveitis usually does not occur from a single inflammatory episode; rather, cumulative damage results from recurrent episodes of inflammation.
- the inflammatory sequelae resulting in vision loss may include one or more of cystoid macular edema, cataracts, vitreous debris, glaucoma, macular pathology (scarring and atrophy) , optic neuropathy, and retinal detachment.
- Anterior uveitis occurs in the front of the eye and is the most common form of uveitis.
- Par planitis is an inflammation of the pars plana, a narrow area between the iris and the choroid.
- Posterior uveitis chondroitis
- Posterior uveitis affects primarily the choroid; the back portion of the uveal tract. If the retina is also involved, it is called chorioretinitis.
- Posterior uveitis may occur in association with an autoimmune disease, or follow a systemic infection. In posterior uveitis, inflammation can last from months to years and may cause permanent vision damage, even with treatment.
- Uveitis can cause vision impairment, ocular pain, and loss of vision. It is estimated that about 10%of new cases of blindness in the U.S. are caused by uveitis. Approximately 300,000 people suffer from uveitis in the U.S. alone, the majority of whom are affected by anterior uveitis.
- the only therapeutic class approved by the FDA for treatment of uveitis is corticosteroids, which are noted for multiple side effects, such as hypertension, hyperglycemia, and hypercholesterolemia, and in the eye, glaucoma and cataract formation.
- Conjunctivitis pink eye
- Keratitis is an inflammation of the cornea (clear portion in the front of the eye) . Keratitis can be caused by an infection (bacterial, fungal, viral, parasite, etc. ) or a non-infectious agent (e.g., certain types of auto-immune diseases are associated with a variety of non-infectious keratitises) .
- an infection bacterial, fungal, viral, parasite, etc.
- a non-infectious agent e.g., certain types of auto-immune diseases are associated with a variety of non-infectious keratitises
- Keratoconjunctivitis refers to an inflammation of the cornea and conjunctiva.
- Vernal keratoconjunctivitis is a recurrent ocular inflammatory disease characterized by hard, elevated, cobblestone like bumps on the upper eyelid. There may also be swellings and thickening of the conjunctiva.
- the conjunctiva is the outermost membrane which lines the eyelids as well as the exposed parts of the eye, except for the cornea.
- Atopic keratoconjunctivitis is the result of a condition called atopy.
- Atopy is a genetic condition whereby the immune system produces higher than normal antibodies in response to a given allergen.
- Systemic immune mediated diseases such as cicatrizing conjunctivitis and other autoimmune disorders of the ocular surface represent a clinically heterogeneous group of conditions where acute and chronic autoreactive mechanisms can cause significant damage to the eye.
- cicatrization can ensue, leading to significant mechanical alterations as a result of the fibrosis.
- These conditions though generally infrequent, can be the cause of profound pathology and visual disability.
- Blepharitis is a common condition that causes inflammation of the eyelids.
- Scleritis is a serious inflammatory disease that affects the white outer coating of the eye, known as the sclera.
- Age-related macular degeneration is a disease associated with aging that gradually destroys sharp, central vision. AMD affects the macula, which is located at the center of the retina. AMD occurs in two forms: wet and dry.
- Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula. These new blood vessels tend to be very fragile and often leak blood and fluid. The blood and fluid raise the macula from its normal place at the back of the eye. Damage to the macula occurs rapidly.
- Dry AMD occurs when the light-sensitive cells in the macula slowly break down, gradually blurring central vision in the affected eye.
- Diabetic retinopathy is a complication of diabetes that results from damage to the blood vessels of the light-sensitive tissue at the back of the eye (the retina) .
- the retina the blood vessels of the light-sensitive tissue at the back of the eye
- DME Diabetic macular edema
- Ocular neovascularization is the abnormal or excessive formation of blood vessels in the eye. Ocular neovascularization has been shown in diabetic retinopathy and age-related macular degeneration (AMD) .
- AMD age-related macular degeneration
- PVR Proliferative vitreoretinopathy
- CMV cytomegalovirus
- HAV disease
- organ or bone marrow transplant or chemotherapy
- CMV virus can cause damage and disease to the eye and the rest of the body.
- CMV affects the eye in about 30%of the cases by causing damage to the retina. This is called CMV retinitis.
- Optic neuritis occurs when the optic nerve becomes inflamed and the myelin sheath becomes damaged or is destroyed. Nerve damage that occurs in the section of the optic nerve located behind the eye, is called retrobulbar neuritis, which is another term sometimes used for optic neuritis.
- Epiretinal membrane (macular pucker) is a scar-tissue like membrane that forms over the macula. It typically progresses slowly and affects central vision by causing blurring and distortion. As it progresses, the pulling of the membrane on the macula may cause swelling.
- retinitis pigmentosa SAMD11, EMC1, DHDDS, RP59, POMGNT1, MDDGA3, MDDGB3, MDDGC3, RP76, RPE65, LCA2, RP20
- NPHP4 or SLSN4 recessive Senior-Loken syndrome
- EPN or DFNB36 recessive Usher syndrome
- NMNAT1, LCA9, or PNAT1 recessive Leber congenital amaurosis
- NMNAT1, LCA9, or PNAT1 dominant optic atrophy with neuropathy and myopathy or dominant Charcot-Marie-Tooth disease
- MFN2, CMT6, CMT2A2, or MARF recessive benign fleck retina
- PLA2G5 dominant optic atrophy, deafness, ichthyosis and neuronal disorders
- ELOVL1 recessive Stargardt disease, juvenile and late onset, recessive macular dystrophy, recessive retinitis pigmentosa, reces
- treatable retinal diseases and the responsible genes include, without limitation: achromatopsia (CNGA3, CNGB3) , choroideremia (REP1) , Leber congenital amaurosis (CEP290, GUCY2D, RPE65) , Leber hereditary optic neuropathy (ND4) , Retinoschisis (RS1) , Retinitis pigmentosa (PDE6B, RHO, RPE65, USH2A, RLBP1) , Usher syndrome (MYO7A, USH2A) , X-linked RP (RPGR) , and age-related macular degeneration (ABCA4, ARMS2, C2, C3, CFB, CFH, ERCC6, FBLN5, HMCN1, HTRA1, RAX2, TLR3, TLR4, anti-VEGF antibodies) .
- achromatopsia CNGA3, CNGB3
- REP1 choroideremia
- CEP290 Leber congenital amaurosis
- the rAAV viral particle comprising the modified AAV capsid of the invention is administered to a patient to treat neurological disorders, including CNS diseases or disorders, in the patient.
- the treatment of neurological disorders with modern medical and surgical approaches remains difficult for many reasons, such as the complexity of the CNS, the limited regenerative capacity of the tissue, and the difficulty in conveying conventional drugs to the organ due to the blood–brain barrier (BBB) .
- BBB blood–brain barrier
- Gene therapy allowing the delivery of genetic materials that encodes potential therapeutic molecules, represents an attractive option. Gene therapy can result in a stable or inducible expression of transgene (s) , and can allow a nearly specific expression in target cells. Not only considered for rare inherited disorders, gene therapy may also open treatment opportunities for more challenging and complex diseases such as Alzheimer’s or Parkinson’s disease.
- gene therapy using viral vectors –encoding a therapeutic gene or inhibitory RNA into a viral capsid and supplying it to the nervous system has emerged as a clinically viable option for therapy of neurological disorders. Indeed, AAV vectors have been shown to mediate safe and long-term gene transfer to the brains of rodents, monkeys, and humans.
- AAV vectors based on AAV2 were too inefficient for many applications that require more widespread gene transfer in the brain.
- second generation vectors such as the human isolate AAV9, are substantially more efficient and show potential for expanding the applications of CNS gene transfer to diseases that impact the entire CNS.
- AAV9 can cross the BBB to transduce cells within the CNS after intravenous delivery, an approach which has already shown promise in infants with SMA (FDA approved drug: Zolgensma) .
- SMA FDA approved drug: Zolgensma
- trans-BBB AAV9 delivery is efficient in mice, the inefficiency of this approach when scaled to larger animals necessitates extremely large vector doses. These doses result in high levels of transduction in peripheral organs with potential associated toxicity, and face manufacturing limitations that may preclude clinical applications beyond the treatment of infants.
- CSF cerebrospinal fluid
- the optimal route of vector administration into the CSF is determined.
- the rAAV viral particle comprising the modified AAV capsid of the invention is administered into cerebrospinal fluid (CSF) .
- CSF cerebrospinal fluid
- lumbar puncture is used as a minimally invasive way for administration of the rAAV viral particles comprising the modified AAV capsid of the invention.
- the rAAV is administered via intravitreal injection.
- the rAAV is administered via subretinal injection.
- the rAAV is administered via intrathecal injection, such as lumbar puncture-intrathecal injection.
- intrathecal administration refers to the administration of an agent, e.g., a composition comprising a rAAV, into the spinal canal.
- intrathecal administration may comprise injection in the cervical region of the spinal canal, in the thoracic region of the spinal canal, or in the lumbar region of the spinal canal.
- intrathecal administration is performed by injecting an agent, e.g., a composition comprising the rAAV viral particle of the invention, into the subarachnoid cavity (subarachnoid space) of the spinal canal, which is the region between the arachnoid membrane and pia mater of the spinal canal.
- the subarchnoid space is occupied by spongy tissue consisting of trabecula (delicate connective tissue filaments that extend from the arachnoid mater and blend into the pia mater) and intercommunicating channels in which the cerebrospinal fluid is contained.
- intrathecal administration is not administration into the spinal vasculature.
- the rAAV viral particle comprising the modified AAV capsid of the invention is administered to a patient to treat CNS diseases or disorders, in the patient.
- a “CNS-related disorder” is a disease or condition of the central nervous system.
- the treatable CNS-related disorder affects the spinal cord (e.g., a myelopathy) , brain (e.g., a encephalopathy) or tissues surrounding the brain and spinal cord.
- the treatable CNS-related disorder is of a genetic origin, either inherited or acquired through a somatic mutation.
- the treatable CNS-related disorder is a psychological condition or disorder, e.g., Attention Deficient Hyperactivity Disorder, Autism Spectrum Disorder, Mood Disorder, Schizophrenia, Depression, Rett Syndrome, etc.
- the treatable CNS-related disorder is an autoimmune disorder.
- the treatable CNS-related disorder is a cancer of the CNS, e.g., brain or spinal cord cancer and/or tumors.
- the treatable CNS-related disorder is a cancer that may be a primary cancer of the CNS, e.g., an astrocytoma, glioblastomas, etc., or may be a cancer that has metastasized to CNS tissue, e.g., a lung cancer that has metastasized to the brain.
- treatable CNS-related disorders include Parkinson's Disease, Lysosomal Storage Disease, Ischemia, Neuropathic Pain, Amyotrophic lateral sclerosis (ALS) , Multiple Sclerosis (MS) , and Canavan disease (CD) .
- the CNS disease or disorder is Alzheimer’s disease (AD) , Lewy body dementia, frontotemporal dementia, Huntington’s disease, stroke, and traumatic brain injury.
- AD Alzheimer’s disease
- Lewy body dementia Lewy body dementia
- frontotemporal dementia Huntington’s disease
- stroke stroke
- traumatic brain injury traumatic brain injury
- the CNS disease or disorder brain or spinal cord injury Bell's palsy, Cerebral palsy, cervical spondylosis, carpal tunnel syndrome, Huntington's disease, Motor neuron disease (MND) , Neurofibromatosis, peripheral neuropathy, Guillain-Barré syndrome, dementia, headache, epilepsy, dizziness, and neuralgia.
- MND Motor neuron disease
- treatable CNS disease-responsible genes include, without limitation: apolipoprotein E (ApoE) , apoE2, survival motor neuron 1 (SMN1) , acid alpha-glucosidase (GAA) , CLN3, aspartoacylase protein (ASPA) , Aromatic L-amino acid decarboxylase (AADC) , lysosomal tripeptidyl peptidase I (TPP1) , GLB1, N-sulfoglycosamine sulfohydrolase (SGSH) , alpha-N-acetylglucosaminidase (NAGLU) , iduronate 2-sulfatase (IDS) , NPC1, frataxin (FXN) , GAN, Glial cell line-derived neurotrophic factor (GDNF) , CLN6 Transmembrane ER Protein, alpha-L-iduronidase (IDUA) ,
- the GOI of the invention to be encompassed by the AAV vector genome encapsidated with the modified AAV capsids of the invention includes any one of the known target genes (such as the ones disclosed herein) responsible for any of the CNS disorders disclosed herein, e.g., target genes the expression of which, as the GOI carried by the AAV vectors of the invention, alleviates at least one symptom of the respective CNS disorders.
- the GOI of the invention to be encompassed by the AAV vector genome encapsidated with the modified AAV capsids of the invention includes an agent that antagonizes the function /expression of any one of the known target genes responsible for any of the CNS disorders disclosed herein, e.g., target genes the expression of which is associated with or causative of at least one symptom of the CNS disorders, and the down-regulation of the expression of which by the agent (that antagonizes the function /expression of the known target genes) alleviates at least one symptom of the CNS disorders.
- antagonizing agents include any one or more of: ZFN, TALEN, or CRISPR system nucleases (that targets the dominant disease genes, and/or be used as tools for correcting genes or modulating gene expression) ; antibodies or antigen binding fragments thereof (that neutralize a gene product of the dominant disease genes, such as anti-VEGF antibody) ; RNAi reagents (siRNA, shRNA, miRNA etc) , antisense polynucleotides, or other non-coding polynucleotides (that down-regulate the expression of the dominant disease genes) , etc.
- Another aspect of the invention provides an AAV viral vector comprising the GOI-containing polynucleotide that can be encapsidated into a capsid shell comprising the modified AAV capsid of the invention.
- the invention further provides a vector (such as plasmids, HSV based vector, or baculovirus vector) that can be used for producing the subject AAV viral vector.
- a vector such as plasmids, HSV based vector, or baculovirus vector
- the vector comprises a polynucleotide encoding any one of the modified AAV capsid of the invention.
- the vector is an HSV vector comprising a coding sequence for a rep and a cap gene of AAV, which cap gene encodes any one of the modified AAV capsid of the invention.
- HSV vector may be used with another HSV vector comprising a GOI flanked by an pair of AAV ITR sequence coding sequences, to co-infect a producer cell to generate AAV viral particles comprising the modified AAV capsid of the invention encapsidating the ITR-flanked GOI.
- the vector is baculoviral vector comprising a coding sequence for a rep and a cap gene of AAV, which cap gene encodes any one of the modified AAV capsid of the invention.
- baculoviral vector may be used with another baculoviral vector comprising a GOI flanked by an pair of AAV ITR sequence coding sequences, to co-infect an insect producer cell (such as Sf9) to generate AAV viral particles comprising the modified AAV capsid of the invention encapsidating the ITR-flanked GOI.
- a “vector” generally refers to a composition of matter which comprises an isolated nucleic acid (DNA or RNA) and which can be used to deliver the isolated nucleic acid to the interior of a cell.
- the vector may be an expression vector.
- “Expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed.
- An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system.
- Expression vectors include all those known in the art, such as cosmids, plasmids, bacmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.
- vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses.
- vector includes an autonomously replicating plasmid or a virus.
- the term should also be construed to include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the like.
- viral vectors include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, and the like.
- the invention provides an isolated rAAV viral particle comprising a GOI-containing polynucleotide encapsidated in any one of the modified AAV capsid of the invention described herein.
- the rAAV genome may be either a single-stranded (ss) nucleic acid or a double stranded (ds) , self-complementary (sc) nucleic acid.
- a related aspect of the invention also provides a population of isolated rAAV viral particle of the invention.
- the population of rAAV particles contain a plurality of rAAV viral particle of the invention, wherein about 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%or more of the rAAV particles within the population have encapsidated GOI-containing polynucleotide sequence of the invention.
- Packaging cells are used to form virus particles that are capable of infecting a host cell.
- Such cells include HEK293, HEK293T and Sf9 cells, which can be used to package AAV and adenovirus.
- Viral vectors used in gene therapy are usually generated by a producer cell line that packages a nucleic acid vector into a viral particle.
- the vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host (if applicable) , other viral sequences being replaced by an expression cassette encoding the protein to be expressed.
- the missing viral functions can be supplied in trans by the packaging cell line, usually as a result of expression of these viral functions /proteins (such as the rep and cap genes for AAV) either as transgenes integrated into the packaging cell, or as transgenes on a second viral vector or expression vector introduced into the packaging cell.
- AAV vectors used in gene therapy typically only possess inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and integration into the host genome.
- Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences.
- the cell line is also infected with adenovirus as a helper.
- the helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid.
- the helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.
- recombinant AAVs may be produced using the triple transfection method (described in detail in U.S. Pat. No. 6,001,650) .
- the recombinant AAVs are produced by transfecting a host cell with an recombinant AAV vector (comprising a gene of interest) to be packaged into AAV particles, an AAV helper function vector, and an accessory function vector.
- An AAV helper function vector encodes the “AAV helper function” sequences (e.g., rep and cap) , which function in trans for productive AAV replication and encapsidation.
- the AAV helper function vector supports efficient AAV vector production without generating any detectable wild-type AAV virions (e.g., AAV virions containing functional rep and cap genes) .
- the accessory function vector encodes nucleotide sequences for non-AAV derived viral and/or cellular functions upon which AAV is dependent for replication (e.g., “accessory functions” ) .
- the accessory functions include those functions required for AAV replication, including, without limitation, those moieties involved in activation of AAV gene transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of cap expression products, and AAV capsid assembly.
- Viral- based accessory functions can be derived from any of the known helper viruses such as adenovirus, herpesvirus (other than herpes simplex virus type-1) , and vaccinia virus.
- the subject rAAV is produced using a baculovirus expression system packaged in insect cells such as Sf9 cells.
- insect cells such as Sf9 cells.
- a baculovirus expression system packaged in insect cells such as Sf9 cells. See, for example, WO2007046703, WO2007148971, WO2009014445, WO2009104964, WO2013036118, WO2011112089, WO2016083560, WO2015137802, and WO2019016349, all incorporated herein by reference.
- the vector titers are usually expressed as viral genomes per ml (vg/ml) .
- viral titers is above 1x10 9 , above 5x10 10 , above 1x10 11 , above 5x10 11 , above 1x10 12 , above 5x10 12 , or above 1x10 13 vg/ml.
- the second generation vector AAV9 has a more general distribution of expression throughout the body in a mice model, and it also shows potential for crossing the blood-brain barrier (BBB) to transduce central nervous system (CNS) .
- BBB blood-brain barrier
- CNS central nervous system
- AAV9 could also efficiently infect retinal cells (including RPE, muller, PR cells, especially cones) in both mice and NHPs. Therefore, AAV9 is an ideal parental AAV vector to be modified or optimized to obtain novel AAV vectors with improved properties.
- the transgene plasmid AAV-CAG-tdTomato vector, was used to offer a reporter gene to be packaged into the indicated AAV capsids.
- pAAV-rep2/cap9 and pAAV-rep2/cap9-variants were synthesized in BBI Life Sciences Corporation.
- pHelper was a helper plasmid containing AdV genes that serve helper function for AAV virus generation.
- Recombinant AAVs were generated by triple transfection of 293T cells using polyethylenimine (PEI) .
- Viral particles were harvested from the media at 72 hrs post transfection and from the cells and media at 120 hrs.
- Cell pellets were resuspended in 10 mM Tris with 10 mM MgCl 2 and 150 mM sodium chloride, pH 7.6, freeze-thawed three times, and treated with 125 U/mL Benzonase (Sigma) at 37°C for at least 1 hr.
- Viral media was concentrated by precipitation with 10%polyethylene glycol 8000 (Sigma-Aldrich) with 625 mM sodium chloride, resuspended in PBS with 0.001%Pluronic TM F-68 Non-ionic
- Virus titers were determined by measuring the number of DNase I resistant vector genomes using qPCR with linearized genome plasmid as a standard.
- C57BL/6J animals were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in on-site animal facility on 12 hr: 12 hr light/dark cycle with ad libitum food and water intake. All experimental protocols were approved by the Animal Care and Use Committee.
- mice were randomly assigned to groups. Eight-week-old C57B1/6 mice were injected with 1 ⁇ L (5E10 8 vg) rAAVs into the subretinal space of the eye. Four (4) weeks after injection, the mice were sacrificed and organs were collected.
- mice were randomly assigned to groups. Eight-week-old C57B1/6 mice were intravitreally injected with 1 ⁇ L (1E10 9 vg) rAAVs. Four (4) weeks after injection, the mice were sacrificed and organs were collected.
- Neonatal (P0-P2) C57B1/6 mice were injected with 3 ⁇ L (3E10 9 vg) rAAVs into the lumbar space of spinal cord.
- 3E10 9 vg mice were sacrificed and organs were collected.
- mice Four weeks after AAV injection, mice were anesthetized and transcardially perfused with PBS at room temperature (RT) at pH 7.4 and then with freshly prepared, ice-cold 4%paraformaldehyde (PFA) in PB.
- Organs (eyes, spinal cords and brains) were post-fixed in 4%PFA overnight. Brains and spinal cords were embedded with OCT for frozen section after dehydration.
- OCT For the retina complex, a knife cut was made on the cornea before the dehydration step and the lens was removed before embedding.
- Organs or tissues were sectioned at 20 ⁇ m thickness using a freezing microtome (Leica CM1950) and sections were mounted to the slide directly. The slides were baked at 60°C for 1-2 hours followed by incubating with DAPI (1: 1000) for 1 hour. Afterward, images were captured with Nikon Ni-E Motorized Upright Fluorescence Microscope or Nikon C2si+ Confocal Microscope.
- the novel AAVs exhibit greater infectivity of retinal cells when administered via intravitreal injection or subretinal injection compared to wild type AAV.
- the retinal cell can be a PR (e.g., rods; cones) , a retinal ganglion cell (RGC) , a muller cell (a muller glial cell) , a bipolar cell, an amacrine cell, a horizontal cell, or a RPE cell.
- PR e.g., rods; cones
- RRC retinal ganglion cell
- a muller cell a muller glial cell
- AAV9-M5 AAV9-M6 and AAV9-M8 were compared with the parental AAV9.
- vg 2E9 vector genomes
- Confocal scans of retinal cross sections revealed that AAV9-treated eyes had only limited tdTomato signal mainly at the choriod, with only sparse tdTomato-positive cells in the ganglion cell layer.
- a relative low dose 5E 8 vg per eye, was used to better distinguish the transduction efficiency of viral vectors, since AAV9 already has a good transduction ability in mouse retina via subretinal injection.
- retinal sections were analyzed by direct fluorescence evaluation to assess AAV vector tropism. As shown in FIGs. 3A and 3B, all vectors could efficiently transduce the RPE.
- the retinas that received AAV9-M5, AAV9-M6 and AAV9-M8 showed much stronger tdTomato expression in PRs located in ONL.
- AAV9-M8 and, in particular, AAV9-M6 could also reach the inner part of the retina, strongly transduce INL and RGC.
- the overall retina transduction efficiency of AAV9 variants are much better, especially AAV9-M6.
- AAV9-M5 AAV9-M6 and AAV9-M8 were compared with the parental AAV9.
- AAV9 variants and AAV9 were used to package a single-stranded (ss) tdTomato reporter driven by the ubiquitous CAG promoter (ss-CAG-tdTomato) .
- ss-CAG-tdTomato ubiquitous CAG promoter
- About 3E 9 vg of each vector were administered to neonatal mice (P0-P2) by intrathecal injection, and tdTomato expression was assessed 4 weeks later.
- the AAV9-M5 and, in particular, AAV9-M8 appeared to transduce the CNS more efficiently than AAV9 as judged by microscopy on thin sections from the brain and the spinal cord (FIGs. 4A and 4B) .
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne de nouvelles capsides AAV pour un tropisme amélioré vers des tissus neuronaux et l'œil, pour générer des vecteurs viraux AAV recombinants.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/106935 WO2023283962A1 (fr) | 2021-07-16 | 2021-07-16 | Capside aav modifiée pour thérapie génique et méthodes associées |
CN202280054384.8A CN117858891A (zh) | 2021-07-16 | 2022-07-15 | 用于基因疗法的经修饰aav衣壳及其方法 |
PCT/CN2022/106118 WO2023284879A1 (fr) | 2021-07-16 | 2022-07-15 | Capside aav modifiée pour thérapie génique et méthodes associées |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/106935 WO2023283962A1 (fr) | 2021-07-16 | 2021-07-16 | Capside aav modifiée pour thérapie génique et méthodes associées |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023283962A1 true WO2023283962A1 (fr) | 2023-01-19 |
Family
ID=77563860
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/106935 WO2023283962A1 (fr) | 2021-07-16 | 2021-07-16 | Capside aav modifiée pour thérapie génique et méthodes associées |
PCT/CN2022/106118 WO2023284879A1 (fr) | 2021-07-16 | 2022-07-15 | Capside aav modifiée pour thérapie génique et méthodes associées |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/106118 WO2023284879A1 (fr) | 2021-07-16 | 2022-07-15 | Capside aav modifiée pour thérapie génique et méthodes associées |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117858891A (fr) |
WO (2) | WO2023283962A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117850367A (zh) * | 2023-12-29 | 2024-04-09 | 淮阴工学院 | 一种基于多生产线的vmd分解与生产线优化系统 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1995013365A1 (fr) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Production de titres eleves de vecteurs d'aav recombinants |
WO1995013392A1 (fr) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Lignees cellulaires stables aptes a exprimer le gene de replication du virus adeno-associe |
WO1996017947A1 (fr) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Lignees cellulaires d'encapsidation utilisees pour la generation de titres hauts de vecteurs aav recombinants |
WO1997006243A1 (fr) | 1995-08-10 | 1997-02-20 | Pasteur Merieux Serums Et Vaccins | Procede de purification de virus par chromatographie |
WO1997008298A1 (fr) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Purification d'adenovirus et de virus adeno-associe (aav) par voie chromatographique |
WO1997009441A2 (fr) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Vecteurs aav ameliores pour la therapie genique |
WO1997021825A1 (fr) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Procede de production de lignees de cellules d'encapsidation retrovirales generant un surnageant retroviral a efficacite de transduction elevee |
US5786211A (en) | 1994-06-06 | 1998-07-28 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5871982A (en) | 1994-10-28 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
WO1999011764A2 (fr) | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Procedes de generation de preparations de vecteurs de aav recombinants dont le titre est eleve et qui sont exemptes de virus assistant |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2007046703A2 (fr) | 2005-10-20 | 2007-04-26 | Amsterdam Molecular Therapeutics B.V. | Vecteurs aav ameliores produits dans des cellules d'insecte |
WO2007148971A2 (fr) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vecteurs aav avec séquences de codage rep ameliorées pour une production dans des cellules d'insecte |
WO2009014445A2 (fr) | 2007-07-26 | 2009-01-29 | Amsterdam Molecular Therapeutics B.V. | Vecteurs baculoviraux comprenant des séquences codantes répétées avec des erreurs systématiques de codon différentiel |
WO2009104964A1 (fr) | 2008-02-19 | 2009-08-27 | Amsterdam Molecular Therapeutics B.V. | Optimisation de l'expression de protéines rep et cap parvovirales dans des cellules d'insectes |
US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
WO2011112089A2 (fr) | 2010-03-11 | 2011-09-15 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Séquences codant une protéine rep mutée destinées à être utilisées dans la production de vaa |
WO2013036118A1 (fr) | 2011-09-08 | 2013-03-14 | Uniqure Ip B.V. | Élimination de virus contaminants à partir de préparations de virus adéno-associés (vaa) |
WO2015121501A1 (fr) | 2014-02-17 | 2015-08-20 | King's College London | Vecteur viral adéno-associé |
WO2015137802A1 (fr) | 2014-03-10 | 2015-09-17 | Uniqure Ip B.V. | Vecteurs aav encore améliorés produits dans des cellules d'insectes |
WO2016083560A1 (fr) | 2014-11-28 | 2016-06-02 | Uniqure Ip B.V. | Impuretés de type adn dans une composition comprenant un virion de parvovirus |
US9818600B2 (en) | 2014-03-21 | 2017-11-14 | Hitachi Kokusai Electric, Inc. | Substrate processing apparatus and method of manufacturing semiconductor device |
US20180066279A9 (en) | 2014-04-25 | 2018-03-08 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
WO2019016349A1 (fr) | 2017-07-20 | 2019-01-24 | Uniqure Ip B.V. | Production de capsides de vaa améliorées dans des cellules d'insectes |
WO2020077165A1 (fr) * | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions et procédés pour l'administration d'aav |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI3445773T3 (fi) * | 2016-05-13 | 2023-03-30 | 4D Molecular Therapeutics Inc | Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä |
EP3813845A4 (fr) * | 2018-05-15 | 2022-10-26 | President And Fellows Of Harvard College | Vecteurs viraux présentant des propriétés d'insertion de gènes améliorées |
TW202102526A (zh) * | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
IL291944A (en) * | 2019-10-10 | 2022-06-01 | Solid Biosciences Inc | Modified aav capsids and uses thereof |
WO2021073568A1 (fr) * | 2019-10-16 | 2021-04-22 | Wuxi Apptec (Shanghai) Co., Ltd. | Nouveau variant d'aav |
-
2021
- 2021-07-16 WO PCT/CN2021/106935 patent/WO2023283962A1/fr unknown
-
2022
- 2022-07-15 CN CN202280054384.8A patent/CN117858891A/zh active Pending
- 2022-07-15 WO PCT/CN2022/106118 patent/WO2023284879A1/fr active Application Filing
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5658776A (en) | 1993-11-09 | 1997-08-19 | Targeted Genetics Corporation | Generation of high titers of recombinant AAV vectors |
WO1995013365A1 (fr) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Production de titres eleves de vecteurs d'aav recombinants |
WO1995013392A1 (fr) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Lignees cellulaires stables aptes a exprimer le gene de replication du virus adeno-associe |
US5786211A (en) | 1994-06-06 | 1998-07-28 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5871982A (en) | 1994-10-28 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
WO1996017947A1 (fr) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Lignees cellulaires d'encapsidation utilisees pour la generation de titres hauts de vecteurs aav recombinants |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
WO1997006243A1 (fr) | 1995-08-10 | 1997-02-20 | Pasteur Merieux Serums Et Vaccins | Procede de purification de virus par chromatographie |
WO1997008298A1 (fr) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Purification d'adenovirus et de virus adeno-associe (aav) par voie chromatographique |
WO1997009441A2 (fr) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Vecteurs aav ameliores pour la therapie genique |
WO1997021825A1 (fr) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Procede de production de lignees de cellules d'encapsidation retrovirales generant un surnageant retroviral a efficacite de transduction elevee |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
WO1999011764A2 (fr) | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Procedes de generation de preparations de vecteurs de aav recombinants dont le titre est eleve et qui sont exemptes de virus assistant |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2007046703A2 (fr) | 2005-10-20 | 2007-04-26 | Amsterdam Molecular Therapeutics B.V. | Vecteurs aav ameliores produits dans des cellules d'insecte |
US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
WO2007148971A2 (fr) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vecteurs aav avec séquences de codage rep ameliorées pour une production dans des cellules d'insecte |
WO2009014445A2 (fr) | 2007-07-26 | 2009-01-29 | Amsterdam Molecular Therapeutics B.V. | Vecteurs baculoviraux comprenant des séquences codantes répétées avec des erreurs systématiques de codon différentiel |
WO2009104964A1 (fr) | 2008-02-19 | 2009-08-27 | Amsterdam Molecular Therapeutics B.V. | Optimisation de l'expression de protéines rep et cap parvovirales dans des cellules d'insectes |
WO2011112089A2 (fr) | 2010-03-11 | 2011-09-15 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Séquences codant une protéine rep mutée destinées à être utilisées dans la production de vaa |
WO2013036118A1 (fr) | 2011-09-08 | 2013-03-14 | Uniqure Ip B.V. | Élimination de virus contaminants à partir de préparations de virus adéno-associés (vaa) |
WO2015121501A1 (fr) | 2014-02-17 | 2015-08-20 | King's College London | Vecteur viral adéno-associé |
WO2015137802A1 (fr) | 2014-03-10 | 2015-09-17 | Uniqure Ip B.V. | Vecteurs aav encore améliorés produits dans des cellules d'insectes |
US9818600B2 (en) | 2014-03-21 | 2017-11-14 | Hitachi Kokusai Electric, Inc. | Substrate processing apparatus and method of manufacturing semiconductor device |
US20180066279A9 (en) | 2014-04-25 | 2018-03-08 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
WO2016083560A1 (fr) | 2014-11-28 | 2016-06-02 | Uniqure Ip B.V. | Impuretés de type adn dans une composition comprenant un virion de parvovirus |
WO2019016349A1 (fr) | 2017-07-20 | 2019-01-24 | Uniqure Ip B.V. | Production de capsides de vaa améliorées dans des cellules d'insectes |
WO2020077165A1 (fr) * | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions et procédés pour l'administration d'aav |
Non-Patent Citations (27)
Title |
---|
CARTER, CURRENT OPINIONS IN BIOTECHNOLOGY, 1992, pages 1533 - 539 |
CHAPMANROSSMANN: "Structure, sequence, and function correlations among parvoviruses", VIROLOGY, vol. 194, 1993, pages 491 - 508, XP002924108, DOI: 10.1006/viro.1993.1288 |
CHOI ET AL., MOL BRAIN, vol. 7, 2014, pages 17 |
CLARK ET AL., GENE THERAPY, vol. 3, 1996, pages 1124 - 1132 |
DATABASE Geneseq [online] 11 June 2020 (2020-06-11), MURLIDHARAN G ET AL: "Adeno-associated virus capsid protein (VOY701), SEQ 1829.", XP055874308, retrieved from EBI accession no. GSP:BHQ85729 Database accession no. BHQ85729 * |
DEVERMAN ET AL., NATURE BIOTECHNOLOGY, vol. 34, no. 2, 2016, pages 204 - 209 |
GOODWINROTTMAN, J BIOL CHEM., vol. 267, no. 23, 15 August 1992 (1992-08-15), pages 16330 - 4 |
GRIMM ET AL., JOURNAL OF VIROLOGY, vol. 82, no. 12, 2008, pages 5887 - 5911 |
HANEN K ET AL: "Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8", BIOTECHNOLOGY AND BIOENGINEERING, JOHN WILEY, HOBOKEN, USA, vol. 113, no. 12, 30 June 2016 (2016-06-30), pages 2712 - 2724, XP071165912, ISSN: 0006-3592, DOI: 10.1002/BIT.26031 * |
HERMONAT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6466 |
KALEV-ZYLINSKA, J NEUROSCI, vol. 27, 2007, pages 10456 - 10467 |
LEBKOWSKI ET AL., MOL. CELL. BIOL, vol. 7, 1988, pages 349 |
LIU ET AL., GENE THER, vol. 20, 2013, pages 308 - 317 |
LU ET AL., HUM GENE THER, vol. 28, no. 1, 2017, pages 125 - 134 |
LU, M / GENET GENOMICS, vol. 279, 2008, pages 563 - 572 |
MCLAUGHLIN ET AL., J. VIROL, vol. 62, 1988, pages 1963 |
MUZYCZKA, CURR. TOPICS IN MICROBIAL, AND IMMUNOL, vol. 158, 1992, pages 97 - 129 |
PARR ET AL., NAT. MED., vol. 3, 1997, pages 1145 - 9 |
PAUL ET AL., HUMAN GENE THERAPY, vol. 4, 1993, pages 609 - 615 |
PERRIN ET AL., VACCINE, vol. 13, 1995, pages 1244 - 1250 |
PULICHERLA ET AL., MOLECULAR THERAPY, vol. 19, no. 6, 2011, pages 1070 - 1078 |
RATSCHIN ET AL., MOL. CELL. BIOL., vol. 4, 1984, pages 2072 |
SAMULSKI ET AL., J. VIROL, vol. 63, 1989, pages 3822 - 3828 |
SNYDER ET AL., HUM GENE THER, vol. 8, 1997, pages 1891 - 1900 |
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 3251 |
TSAO, SCIENCE, vol. 251, 1991, pages 1456 - 1464 |
XIE, PROC. NATL. ACAD. SCI. USA., vol. 99, 2002, pages 10405 - 10410 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117850367A (zh) * | 2023-12-29 | 2024-04-09 | 淮阴工学院 | 一种基于多生产线的vmd分解与生产线优化系统 |
Also Published As
Publication number | Publication date |
---|---|
WO2023284879A1 (fr) | 2023-01-19 |
CN117858891A (zh) | 2024-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220387560A1 (en) | Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease | |
JP6994140B2 (ja) | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖dna | |
JP7237843B2 (ja) | 修飾されたaavキャプシドタンパク質およびその使用 | |
JP2022008560A (ja) | 無カプシドaavベクター、組成物ならびにベクター製造および遺伝子運搬のための方法 | |
JP7385282B2 (ja) | 環状rna分子のための方法及び組成物 | |
US9724429B2 (en) | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases | |
IL296365A (en) | Genetic editing of deep intronic mutations | |
Ortolano et al. | Present and future of adeno associated virus based gene therapy approaches | |
US20240141378A1 (en) | Controlled expression of viral proteins | |
US20210301305A1 (en) | Engineered untranslated regions (utr) for aav production | |
KR102522273B1 (ko) | 로돕신 전사체에 특이적인 트랜스-스플라이싱 라이보자임 및 이의 용도 | |
WO2023284879A1 (fr) | Capside aav modifiée pour thérapie génique et méthodes associées | |
JP2024508696A (ja) | Rnaアデノ随伴ウイルス(raav)ベクター及びその用途 | |
TW202305124A (zh) | 具有腦特異性靶向模體的新穎構成物及含有其之組成物 | |
KR102396200B1 (ko) | 로돕신 전사체에 특이적인 트랜스-스플라이싱 라이보자임 및 이의 용도 | |
WO2023030541A1 (fr) | Traitement de maladies et de troubles oculaires associés à rpe65 | |
WO2023230657A1 (fr) | Protéines de capside de virus adéno-associé modifiées et procédés associés | |
JP2022523050A (ja) | 合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21762998 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |